{ "version": "2.2", "instance": { "phat-20251231.htm": { "nsprefix": "phat", "nsuri": "http://www.phathompharma.com/20251231", "dts": { "inline": { "local": [ "phat-20251231.htm" ] }, "schema": { "local": [ "phat-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] } }, "keyStandard": 341, "keyCustom": 109, "axisStandard": 27, "axisCustom": 1, "memberStandard": 31, "memberCustom": 70, "hidden": { "total": 12, "http://fasb.org/us-gaap/2025": 8, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 234, "entityCount": 1, "segmentCount": 101, "elementCount": 900, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 643, "http://xbrl.sec.gov/dei/2025": 40, "http://xbrl.sec.gov/cyd/2025": 15, "http://xbrl.sec.gov/ecd/2025": 5 }, "report": { "R1": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "75000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets", "longName": "75010 - Statement - Balance Sheets", "shortName": "Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "longName": "75020 - Statement - Balance Sheets (Parenthetical)", "shortName": "Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss", "longName": "75030 - Statement - Statements of Operations and Comprehensive Loss", "shortName": "Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:GrossProfit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R5": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit", "longName": "75050 - Statement - Statements of Stockholders' Deficit", "shortName": "Statements of Stockholders' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_31e8cd15-d8f5-43ad-abcd-c34efda9454e", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_31e8cd15-d8f5-43ad-abcd-c34efda9454e", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows", "longName": "75060 - Statement - Statements of Cash Flows", "shortName": "Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance", "longName": "75080 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance", "shortName": "Cybersecurity Risk Management, Strategy, and Governance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_8b67e81b-fa2e-45e4-a3d8-25620cfa6c68", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "h2", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b67e81b-fa2e-45e4-a3d8-25620cfa6c68", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "h2", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_8b67e81b-fa2e-45e4-a3d8-25620cfa6c68", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b67e81b-fa2e-45e4-a3d8-25620cfa6c68", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "995457 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetails", "longName": "995467 - Disclosure - Balance Sheet Details", "shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995487 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitments", "longName": "995497 - Disclosure - Lease Commitments", "shortName": "Lease Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureDebt", "longName": "995507 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiability", "longName": "995517 - Disclosure - Revenue Interest Financing Liability", "shortName": "Revenue Interest Financing Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:RevenueInterestFinancingLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:RevenueInterestFinancingLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "995527 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognition", "longName": "995537 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995547 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformation", "longName": "995557 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuring1", "longName": "995567 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEvents1", "longName": "995577 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995587 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:OrganizationAndBasisOfPresentationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:OrganizationAndBasisOfPresentationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables", "longName": "995597 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables", "longName": "995607 - Disclosure - Lease Commitments (Tables)", "shortName": "Lease Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureDebtTables", "longName": "995617 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables", "longName": "995627 - Disclosure - Revenue Interest Financing Liability (Tables)", "shortName": "Revenue Interest Financing Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables", "longName": "995637 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables", "longName": "995647 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "longName": "995657 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationTables", "longName": "995667 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringTables", "longName": "995677 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995687 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:MarketingAndAdvertisingExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:MarketingAndAdvertisingExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails", "longName": "995697 - Disclosure - Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)", "shortName": "Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails", "longName": "995707 - Disclosure - Balance Sheet Details - Additional Information (Details)", "shortName": "Balance Sheet Details - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "longName": "995717 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)", "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails", "longName": "995727 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details)", "shortName": "Balance Sheet Details - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995747 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:CommonStockValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:PurchaseCommitmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R39": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails", "longName": "995757 - Disclosure - Lease Commitments - Additional Information (Details)", "shortName": "Lease Commitments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "longName": "995767 - Disclosure - Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)", "shortName": "Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails", "longName": "995777 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)", "shortName": "Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails", "longName": "995797 - Disclosure - Debt - Schedule of Total Debt (Details)", "shortName": "Debt - Schedule of Total Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "longName": "995807 - Disclosure - Debt - Additional Information (Details)", "shortName": "Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d55672d0-a819-405b-b430-9dc638ce84f1", "name": "phat:DebtInstrumentFinalPaymentFee", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R44": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails", "longName": "995817 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)", "shortName": "Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "longName": "995827 - Disclosure - Revenue Interest Financing Liability - Additional Information (Details)", "shortName": "Revenue Interest Financing Liability - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:InvestorsRightToReceiveRoyaltiesTerminationDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "phat:RevenueInterestFinancingLiabilityTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:InvestorsRightToReceiveRoyaltiesTerminationDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "phat:RevenueInterestFinancingLiabilityTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails", "longName": "995837 - Disclosure - Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)", "shortName": "Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_5f55f759-dcb3-4658-b654-ac03e48f557d", "name": "phat:RevenueInterestFinancingLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:RoyaltyPaymentsAndPayables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R47": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "995847 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R48": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "longName": "995857 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)", "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_89d8622b-fc68-411b-a78a-34f0c7ca6077", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R49": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "longName": "995867 - Disclosure - Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)", "shortName": "Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_554725bc-9f3c-42c6-99b4-b9133bca7513", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7bc63975-008a-46b5-992b-7f9590ee03f5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R50": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails", "longName": "995877 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)", "shortName": "Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_3d824763-ccfd-4af0-94ce-72368ef5fa19", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails", "longName": "995887 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_5f55f759-dcb3-4658-b654-ac03e48f557d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R52": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails", "longName": "995897 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "shortName": "Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_188eea6f-7052-468e-bd0c-acb5519c11b3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R53": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "longName": "995907 - Disclosure - Revenue Recognition - Additional Information (Details)", "shortName": "Revenue Recognition - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e4eb5988-9dd7-4679-993e-db9dfb14a8d5", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R54": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails", "longName": "995917 - Disclosure - Revenue Recognition - Summary of Revenue Allowances and Related Accruals (Details)", "shortName": "Revenue Recognition - Summary of Revenue Allowances and Related Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_5f55f759-dcb3-4658-b654-ac03e48f557d", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5f55f759-dcb3-4658-b654-ac03e48f557d", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "995927 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R56": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails", "longName": "995937 - Disclosure - Income Taxes - Schedule Of Pre-tax Net Loss From Operations (Details)", "shortName": "Income Taxes - Schedule Of Pre-tax Net Loss From Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails", "longName": "995957 - Disclosure - Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)", "shortName": "Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails", "longName": "995977 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)", "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails", "longName": "995987 - Disclosure - Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_5f55f759-dcb3-4658-b654-ac03e48f557d", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R60": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "longName": "995997 - Disclosure - Segment Information - Additional Information (Details)", "shortName": "Segment Information - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "longName": "996007 - Disclosure - Segment Information - Schedule of Segment Reporting Financial Information (Details)", "shortName": "Segment Information - Schedule of Segment Reporting Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_64836d14-4b87-4809-a0dd-0a96636bd2b3", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } }, "R62": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "longName": "996017 - Disclosure - Restructuring - Additional Information (Details)", "shortName": "Restructuring - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_7076e73e-e01b-463f-b559-1bf4ae0816d1", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "U_Employee", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7076e73e-e01b-463f-b559-1bf4ae0816d1", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "U_Employee", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails", "longName": "996027 - Disclosure - Restructuring - Summary of Activity Related to Restructuring Accrual (Details)", "shortName": "Restructuring - Summary of Activity Related to Restructuring Accrual (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6738e32-8246-4674-8da6-eae4c9004178", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996037 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_bde8fdfb-e379-4703-8a55-0f169fa6718e", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ca28796c-7652-4358-a505-36a2b238cf03", "name": "phat:DebtInstrumentFinancialConvenantMinimumCashPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20251231.htm", "unique": true } } }, "tag": { "phat_ATMOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ATMOfferingProgramMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "At-the-market offering program.", "label": "A T M Offering Program [Member]", "terseLabel": "At-the-Market Offering Program", "verboseLabel": "ATM Sale Agreement" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingStandardsUpdate201613Member", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update 2016-13", "label": "Accounting Standards Update 2016-13 [Member]", "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." } } }, "auth_ref": [ "r264" ] }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth_ref": [ "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r156", "r157", "r158", "r183", "r184", "r185", "r186", "r187", "r260", "r261", "r265", "r267", "r268", "r284", "r285", "r294", "r355", "r356", "r357", "r358", "r431", "r432", "r433", "r434", "r472", "r473", "r474", "r475", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r496", "r497", "r498", "r499", "r500", "r514", "r515", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r548", "r549", "r565", "r582", "r583", "r584", "r585", "r586", "r587", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699" ] }, "phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AccountsPayableAndAccruedExpensesRelatedPartiesCurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounts payable and accrued expenses related parties current.", "label": "Accounts Payable And Accrued Expenses Related Parties Current", "verboseLabel": "Outstanding accounts payable and accrued expenses" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable, related parties", "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38", "r885" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsReceivableMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r794", "r1117" ] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation expenses", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40" ] }, "phat_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AccruedInterest", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Accrued Interest", "terseLabel": "Accrued interest" } } }, "auth_ref": [] }, "phat_AccruedInterestOnRevenueInterestFinancingLiabilityNetOfPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AccruedInterestOnRevenueInterestFinancingLiabilityNetOfPayments", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued Interest On Revenue Interest Financing Liability Net Of Payments", "documentation": "Accrued interest on revenue interest financing liability net of payments.", "terseLabel": "Accrued interest on revenue interest financing liability, net of payments" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses", "terseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "phat_AccruedPayment-In-KindInterestOnDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AccruedPayment-In-KindInterestOnDebt", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued Payment-In-Kind Interest On Debt", "documentation": "Accrued payment-in-kind interest on debt.", "terseLabel": "Accrued payment-in-kind interest on debt" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional & consulting expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40" ] }, "phat_AccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AccruedResearchAndDevelopmentExpenses", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses.", "label": "Accrued Research And Development Expenses", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "phat_AccruedRevenueAllowancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AccruedRevenueAllowancesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued revenue allowances", "label": "Accrued Revenue Allowances Current", "documentation": "Accrued revenue allowances current." } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense included in accrued expenses", "label": "Accrued Royalties, Current", "verboseLabel": "Royalty expense included in accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40", "r813" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r26", "r136", "r657" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r966" ] }, "phat_AdditionalFundingAchievementOfSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AdditionalFundingAchievementOfSalesMilestone", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional funding achievement of sales milestone", "label": "Additional Funding Achievement Of Sales Milestone", "documentation": "Additional funding achievement of sales milestone." } } }, "auth_ref": [] }, "phat_AdditionalFundingAvailable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AdditionalFundingAvailable", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additional Funding Available", "documentation": "Additional funding available.", "terseLabel": "Additional funding available" } } }, "auth_ref": [] }, "phat_AdditionalLoanTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AdditionalLoanTrancheMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additional Loan Tranche [Member]", "documentation": "Additional loan tranche.", "terseLabel": "Additional Loan Tranche" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r50" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r714", "r1109", "r1110", "r1111", "r1113", "r1195", "r1261" ] }, "phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional percentage to be paid with obligated payment on investment amount.", "label": "Additional Percentage to be Paid with Obligated Payment On Investment Amount", "terseLabel": "Additional percentage to be paid with obligated payment on investment amount" } } }, "auth_ref": [] }, "phat_AdditionalWarrantIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AdditionalWarrantIssued", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional warrant issued.", "label": "Additional Warrant Issued", "terseLabel": "Additional warrant issued" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r979" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r979" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r979" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r979" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r156", "r157", "r158", "r183", "r184", "r185", "r186", "r187", "r198", "r260", "r261", "r265", "r267", "r268", "r269", "r284", "r285", "r294", "r355", "r356", "r357", "r358", "r431", "r432", "r433", "r434", "r471", "r472", "r473", "r474", "r475", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r496", "r497", "r498", "r499", "r500", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r548", "r549", "r565", "r566", "r582", "r583", "r584", "r585", "r586", "r587", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r395" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Adjustments to additional paid-in-capital, warrants issued", "verboseLabel": "Issuance of common stock warrants", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r8", "r29", "r84" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and Marketing Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r107" ] }, "phat_AggregateOfferingPriceThroughEquityFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AggregateOfferingPriceThroughEquityFinancing", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price", "label": "Aggregate offering price through equity financing", "documentation": "Aggregate offering price through equity financing." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1024" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r937", "r948", "r958", "r991" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r940", "r951", "r961", "r994" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1025" ] }, "phat_AgreementExpirationTermFromDateOfFirstCommercialSale": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AgreementExpirationTermFromDateOfFirstCommercialSale", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement expiration term from date of first commercial sale.", "label": "Agreement Expiration Term From Date Of First Commercial Sale", "terseLabel": "Agreement expiration term from date of first commercial sale" } } }, "auth_ref": [] }, "phat_AgreementExtendsPeriodForTermination": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AgreementExtendsPeriodForTermination", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement extends period for termination.", "label": "Agreement Extends Period For Termination", "terseLabel": "Agreement extends period for termination" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r979" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r986" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r941", "r952", "r962", "r986", "r995", "r999", "r1007" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1005" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation cost", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r425", "r435", "r436" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "phat_AmendmentToLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AmendmentToLoanAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amendment to loan agreement.", "label": "Amendment to Loan Agreement [Member]", "terseLabel": "Amendment to Loan Agreement" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt discount", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r65", "r346", "r1098", "r1207" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Unvested shares excluded from computation of weighted average earnings per share", "terseLabel": "Unvested shares excluded from computation of weighted average earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r206" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r206" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r206" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r501" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r93", "r103", "r138", "r166", "r169", "r170", "r209", "r222", "r247", "r251", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r503", "r507", "r552", "r640", "r641", "r648", "r743", "r836", "r837", "r851", "r885", "r902", "r903", "r915", "r1141", "r1142", "r1215" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r131", "r144", "r166", "r169", "r170", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r503", "r507", "r552", "r885", "r1141", "r1142", "r1215" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "phat_AssetsLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AssetsLesseeAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Assets, lessee.", "label": "Assets Lessee [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r920", "r921", "r944" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r920", "r921", "r944" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r920", "r921", "r944" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r1028" ] }, "phat_AvailableAggregateOfferingPriceThroughEquityFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "AvailableAggregateOfferingPriceThroughEquityFinancing", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Available Aggregate offering price through equity financing.", "label": "Available Aggregate offering price through equity financing", "terseLabel": "Available equity financing amount" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1002" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r998" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1001" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1000" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r999" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r999" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BaseRateMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floor Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [ "r1040", "r1140" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r17", "r18", "r19" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "label": "Cash and Cash Equivalent", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r15", "r134", "r811" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r16" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and cash equivalents and restricted cash - end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash - beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r15", "r70", "r165" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation", "totalLabel": "Net decrease in cash and cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1", "r70" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Accounting Standards Update, Adopted", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r123", "r124", "r128", "r156", "r182", "r260", "r284", "r294", "r355", "r431", "r473", "r482", "r483", "r491", "r492", "r496", "r514", "r528", "r529", "r548", "r549", "r565", "r582", "r583", "r688", "r689" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Accounting Standards Update, Adopted Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r123", "r124", "r125", "r156", "r260", "r284", "r294", "r355", "r356", "r431", "r432", "r473", "r482", "r483", "r491", "r492", "r493", "r496", "r497", "r514", "r515", "r528", "r529", "r530", "r533", "r548", "r549", "r565", "r582", "r583", "r688", "r689", "r1034", "r1112" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": [ "r128", "r183", "r197", "r266" ] }, "phat_ChangeInControlDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ChangeInControlDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Change in control description.", "label": "Change in Control Description", "terseLabel": "Change in control description" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r977" ] }, "phat_ChargesForInventoryNotExpectedToBeSoldPriorToItsExpirationDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ChargesForInventoryNotExpectedToBeSoldPriorToItsExpirationDate", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Charges For Inventory Not Expected To Be Sold Prior To Its Expiration Date", "documentation": "Charges for inventory not expected to be sold prior to its expiration date.", "terseLabel": "Charges for inventory not expected to be sold prior to its expiration date" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r974" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r972" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1145" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r166", "r173", "r370" ] }, "phat_ClassOfWarrantOrRightExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ClassOfWarrantOrRightExpirationDate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, expiration date.", "terseLabel": "Warrants expiration date", "label": "Class of Warrant or Right Expiration Date" } } }, "auth_ref": [] }, "phat_ClassOfWarrantOrRightExpireTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ClassOfWarrantOrRightExpireTerm", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, expire term.", "terseLabel": "Warrants expire term", "label": "Class of Warrant or Right Expire Term" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants issued to purchase shares", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued to purchase shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r370" ] }, "phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants issued to common stock remains exercisable", "terseLabel": "Warrants issued to common stock remains exercisable", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Remains Exercisable", "documentation": "Class of warrant or right, number of securities called by warrants or rights, remains exercisable." } } }, "auth_ref": [] }, "phat_ClassOfWarrantsPurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ClassOfWarrantsPurchasePricePerShare", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrants Purchase Price Per Share", "documentation": "Class of warrants purchase price per share.", "terseLabel": "Warrants purchase price" } } }, "auth_ref": [] }, "phat_ClinicalManufacturingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ClinicalManufacturingServicesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Clinical manufacturing services.", "label": "Clinical Manufacturing Services [Member]", "terseLabel": "Clinical Manufacturing Services" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r978" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r978" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Revenue Interest Financing Liability [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r501" ] }, "phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CommercialSupplyAgreementAndTemporaryServicesAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commercial Supply Agreement and Temporary Services Agreement.", "label": "Commercial Supply Agreement and Temporary Services Agreement [Member]", "terseLabel": "Commercial Supply and Temporary Services Agreement" } } }, "auth_ref": [] }, "phat_CommercialSupplyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CommercialSupplyAgreementsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Supply Agreement", "documentation": "Commercial supply agreements." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 3)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r46", "r96", "r650", "r730" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r80", "r307", "r308", "r795", "r1131", "r1137" ] }, "phat_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "auth_ref": [] }, "phat_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (in shares)", "verboseLabel": "Common stock initially reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r905", "r906", "r907", "r909", "r910", "r911", "r912", "r1109", "r1110", "r1113", "r1195", "r1258", "r1261" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r49" ] }, "phat_CommonStockReservedForFutureIssuancesTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CommonStockReservedForFutureIssuancesTableTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Common stock reserved for future issuances.", "label": "Common Stock Reserved For Future Issuances Table Table [Text Block]", "terseLabel": "Summary of Common Stock Reserved for Future Issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares", "verboseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r49", "r731" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "totalLabel": "Common Stock, Shares, Issued, Total", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares", "verboseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares", "terseLabel": "Common stock, outstanding shares", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r49", "r731", "r749", "r1261", "r1262" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock fair value", "terseLabel": "Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2025 and December 31, 2024; issued and outstanding shares - 71,419,025 and 68,518,238 at December 31, 2025 and December 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r49", "r360", "r366", "r652", "r885" ] }, "phat_CommonStockWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CommonStockWarrantMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock warrants", "documentation": "Common stock warrants.", "label": "Common Stock Warrant [Member]", "verboseLabel": "Common Stock Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r983" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r982" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r984" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r981" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r86", "r89" ] }, "phat_ComponentOfBalanceSheetDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ComponentOfBalanceSheetDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "Component of Balance Sheet Disclosure.", "label": "Component Of Balance Sheet Disclosure [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "phat_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment and Related Software" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment and Software", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r212", "r259", "r702", "r703", "r794", "r1116", "r1117", "r1118", "r1119", "r1120" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r212", "r259", "r702", "r703", "r794", "r1116", "r1117", "r1118", "r1119", "r1120" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r212", "r259", "r702", "r703", "r794", "r1116", "r1117", "r1118", "r1119", "r1120" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument." } } }, "auth_ref": [ "r550", "r551" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r212", "r259", "r1116", "r1117", "r1118", "r1119", "r1120" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r212", "r259", "r702", "r703", "r794", "r1116", "r1117", "r1118", "r1119", "r1120" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in Process", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of revenue interest financing liability", "negatedLabel": "Less: current portion", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r372", "r373", "r376", "r386" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue interest financing liability", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r372", "r373", "r376", "r386" ] }, "phat_ContractWithCustomerLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ContractWithCustomerLiabilityTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer, liability.", "label": "Contract with Customer, Liability [Table]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Receivable, after Allowance for Credit Loss", "totalLabel": "Contract with Customer, Receivable, after Allowance for Credit Loss, Total", "periodStartLabel": "Balance as of January 1, 2025", "periodEndLabel": "Balance as of December 31, 2025", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r372", "r374", "r376", "r386", "r793" ] }, "phat_ContractWithCustomerReceivableAllowanceForCreditLossAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ContractWithCustomerReceivableAllowanceForCreditLossAccruals", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals", "label": "Contract with Customer, Receivable, Allowance for Credit Loss, Accruals", "documentation": "Contract with customer, receivable, allowance for credit loss, accruals." } } }, "auth_ref": [] }, "phat_ContractWithCustomerReceivableAllowanceForCreditLossUtilizations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ContractWithCustomerReceivableAllowanceForCreditLossUtilizations", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Utilizations", "label": "Contract with Customer, Receivable, Allowance for Credit Loss, Utilizations", "documentation": "Contract with customer, receivable, allowance for credit loss, utilizations.", "terseLabel": "Utilizations" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "totalLabel": "Cost of Revenue, Total", "terseLabel": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r60", "r166", "r169", "r170", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r552", "r836", "r1141" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r166", "r176", "r177", "r328", "r369", "r594", "r601", "r647", "r815", "r816", "r817", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1190", "r1191", "r1192", "r1193" ] }, "phat_CovenantExtensionAmendmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CovenantExtensionAmendmentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Covenant extension amendment fee", "documentation": "Covenant extension amendment fee.", "terseLabel": "Covenant extension amendment fee" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r259", "r1117" ] }, "phat_CustomerCreditsDiscountsAndAllowanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "CustomerCreditsDiscountsAndAllowanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Customer Credits, Discounts and Allowance [Member]", "documentation": "Customer credits, discounts and allowance.", "terseLabel": "Customer Credits, Discounts and Allowances" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r929", "r1018" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r929", "r1018" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r931", "r1020" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r931", "r1020" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r933", "r1022" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r931", "r1020" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r924", "r1013" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r925", "r1014" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r925", "r1014" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r923", "r1012" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r923", "r1012" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r923", "r1012" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r926", "r1015" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r928", "r1017" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r928", "r1017" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r929", "r1018" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r932", "r1021" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r930", "r1019" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r927", "r1016" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r81", "r166", "r168", "r288", "r289", "r290", "r291", "r292", "r313", "r314", "r324", "r330", "r331", "r332", "r333", "r334", "r335", "r340", "r347", "r348", "r350", "r513", "r563" ] }, "phat_DebtInstrumentAdditionalBorrowingCapacityAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentAdditionalBorrowingCapacityAmounts", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, additional borrowing capacity amount", "label": "Debt Instrument Additional Borrowing Capacity Amounts", "documentation": "Debt instrument additional borrowing capacity amounts." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r12", "r39", "r40", "r94", "r95", "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r846", "r847", "r848", "r849", "r850", "r883", "r1101", "r1102", "r1103", "r1108", "r1132", "r1133", "r1134", "r1206", "r1208", "r1225" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan", "verboseLabel": "Term loans aggregate principal amount", "label": "Long-Term Debt, Gross", "totalLabel": "Total term loan borrowings", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r12", "r95", "r351" ] }, "phat_DebtInstrumentCovenantAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentCovenantAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant [Axis]", "documentation": "Debt instrument covenant axis." } } }, "auth_ref": [] }, "phat_DebtInstrumentCovenantComplianceCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentCovenantComplianceCommitmentAmount", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant Compliance Commitment Amount", "documentation": "Debt Instrument Covenant Compliance Commitment Amount", "terseLabel": "Minimum Cash Covenant, Amount" } } }, "auth_ref": [] }, "phat_DebtInstrumentCovenantCompliancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentCovenantCompliancePercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant Compliance Percentage", "documentation": "Debt instrument covenant compliance percentage.", "terseLabel": "Minimum Cash Covenant, Percentage" } } }, "auth_ref": [] }, "phat_DebtInstrumentCovenantDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentCovenantDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant [Domain]", "documentation": "Debt instrument covenant domain" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount of debt instrument", "verboseLabel": "Debt instrument borrowed amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r325", "r563", "r564", "r847", "r848", "r883" ] }, "phat_DebtInstrumentFacilityChargePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentFacilityChargePercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, facility charge percentage", "label": "Debt Instrument Facility Charge Percentage", "documentation": "Debt instrument facility charge percentage." } } }, "auth_ref": [] }, "phat_DebtInstrumentFacilityFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentFacilityFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Facility Fee", "documentation": "Debt instrument facility fee.", "terseLabel": "Facility fee" } } }, "auth_ref": [] }, "phat_DebtInstrumentFinalPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentFinalPaymentFee", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, final payment fee or end of term charge", "documentation": "Debt instrument final payment fee.", "label": "Debt Instrument Final Payment Fee", "verboseLabel": "Debt instrument, final payment fee or end of term charge" } } }, "auth_ref": [] }, "phat_DebtInstrumentFinalPaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentFinalPaymentFeePercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument final payment fee percentage.", "label": "Debt Instrument Final Payment Fee Percentage", "terseLabel": "Debt instrument, final payment fee percentage" } } }, "auth_ref": [] }, "phat_DebtInstrumentFinancialConvenantMinimumCashPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentFinancialConvenantMinimumCashPercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial convenants, Minimum cash convenant", "label": "Debt Instrument Financial Convenant Minimum Cash Percentage", "documentation": "Debt Instrument Minimum Cash Convenant Percentage." } } }, "auth_ref": [] }, "phat_DebtInstrumentFinancialConvenantsPercentageOfProjectedRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentFinancialConvenantsPercentageOfProjectedRevenue", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial covenants, Projected revenue percentage", "label": "Debt Instrument Financial Convenants Percentage of Projected Revenue", "documentation": "Debt Instrument Financial Convenants Percentage of Projected Revenue." } } }, "auth_ref": [] }, "phat_DebtInstrumentFinancialConvenantsProjectedRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentFinancialConvenantsProjectedRevenue", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial convenants, Projected revenue", "label": "Debt Instrument Financial Convenants Projected Revenue", "documentation": "Debt Instrument Financial Convenants Projected Revenue" } } }, "auth_ref": [] }, "phat_DebtInstrumentInterestAndFinalPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentInterestAndFinalPaymentFee", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest and final payment fee.", "label": "Debt Instrument Interest And Final Payment Fee", "negatedLabel": "Less: payment-in-kind and remaining final payment fees" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r42", "r353", "r563", "r564", "r883" ] }, "phat_DebtInstrumentInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentInterestRatePercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument, interest rate percentage.", "label": "Debt Instrument, Interest Rate Percentage", "terseLabel": "Debt instrument interest rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r42", "r326" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r513", "r644", "r846", "r847", "r848", "r849", "r850", "r883", "r1101", "r1102", "r1103", "r1108", "r1206", "r1208" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r140", "r846", "r1199", "r1200" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r12", "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r846", "r847", "r848", "r849", "r850", "r883", "r1101", "r1102", "r1103", "r1108", "r1132", "r1133", "r1134", "r1206", "r1208", "r1225" ] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentPaymentTerms", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt instrument, description", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": [ "r37", "r43" ] }, "phat_DebtInstrumentPenaltyFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentPenaltyFeePercentage", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument penalty fee percentage", "label": "Debt Instrument Penalty Fee Percentage", "documentation": "Debt instrument penalty fee percentage." } } }, "auth_ref": [] }, "phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment fee percentage of outstanding principal amount.", "label": "Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount", "terseLabel": "Debt instrument, prepayment fee percentage of outstanding principal amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r12", "r30", "r31", "r36", "r82", "r83", "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r513", "r644", "r846", "r847", "r848", "r849", "r850", "r883", "r1101", "r1102", "r1103", "r1108", "r1206", "r1208" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Instrument, Unamortized Discount, Total", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1144", "r1205", "r1206", "r1208" ] }, "phat_DebtinstrumentAmendmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtinstrumentAmendmentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, Amendment fee", "label": "DebtInstrument Amendment Fee", "documentation": "DebtInstrument amendment fee." } } }, "auth_ref": [] }, "phat_DebtinstrumentTrailingNetProductRevenuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DebtinstrumentTrailingNetProductRevenuePeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trailing Net Product Revenue, Period", "label": "DebtInstrument Trailing Net Product Revenue Period", "documentation": "DebtInstrument Trailing Net Product Revenue Period." } } }, "auth_ref": [] }, "phat_DefaultObligationDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DefaultObligationDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Default obligation description.", "label": "Default Obligation Description", "terseLabel": "Default obligation description" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r1187" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r464" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1185" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net of valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1185" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1187" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "verboseLabel": "Operating loss carryforwards which are carried over indefinitely", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } }, "auth_ref": [ "r1187" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1187" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research credits", "verboseLabel": "Research and development credits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r1187" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r465" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1187" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan employer contribution liabilities expense", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r391" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "401(k) matching contribution", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "401(k) matching contribution, shares", "documentation": "Defined contribution pan employer discretionary match number of shares settled.", "label": "Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled", "terseLabel": "Employer discretionary match number of shares settled" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Defined contribution plan, employer matching contribution, percentage", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization, Nonproduction", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r4", "r25" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Total", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r155", "r209", "r227", "r251", "r818", "r836", "r837" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r384", "r385", "r854", "r855", "r856", "r857", "r858", "r859", "r860" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r384", "r385", "r854", "r855", "r856", "r857", "r858", "r859", "r860" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r393", "r397", "r426", "r427", "r430", "r862" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r920", "r921", "r944" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r920", "r921", "r944", "r987" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "verboseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r965" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r918" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DomesticCountryMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "terseLabel": "Federal", "verboseLabel": "Domestic", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r447" ] }, "phat_DrugProductOrSubstanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "DrugProductOrSubstanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Drug Product or Substance", "label": "Drug Product Or Substance [Member]", "documentation": "Drug product Or substance." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r976" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r128", "r152", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r199", "r201", "r203", "r204", "r205", "r208", "r358", "r433", "r489", "r500", "r537", "r538", "r639", "r663", "r825" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r128", "r152", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r201", "r203", "r204", "r205", "r208", "r358", "r433", "r489", "r500", "r537", "r538", "r639", "r663", "r825" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r20", "r21", "r207" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision (benefit) for income taxes", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r447", "r865" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Tax computed at federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r166", "r172", "r447", "r476", "r865" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r452", "r865", "r1101", "r1107", "r1180" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in state rate", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r451", "r865", "r1101", "r1107", "r1180" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r865", "r1101", "r1107", "r1180", "r1181" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "terseLabel": "Stock-based compensation", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1178", "r1180", "r1181" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Stock-based compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1178", "r1180", "r1181" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State tax, net of federal income tax effect", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r450", "r865", "r1101", "r1107", "r1180" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development credit", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedLabel": "Research and development credit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r865", "r1101", "r1107", "r1180", "r1182" ] }, "phat_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in unrecognized tax benefits", "label": "Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits", "documentation": "Effective income tax rate reconciliation unrecognized tax benefits.", "negatedLabel": "Changes in unrecognized tax benefits" } } }, "auth_ref": [] }, "phat_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in unrecognized tax benefits", "label": "Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits Percent", "documentation": "Effective income tax rate reconciliation unrecognized tax benefits percent." } } }, "auth_ref": [] }, "phat_EmployeeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "EmployeeOneMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee One", "label": "Employee One [Member]", "documentation": "Employee one." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1174" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, weighted-average period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r429" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1175" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1175" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Severance", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock Options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "phat_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan", "verboseLabel": "ESPP Plan" } } }, "auth_ref": [] }, "phat_EmployeeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "EmployeeTwoMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Two", "label": "Employee Two [Member]", "documentation": "Employee two." } } }, "auth_ref": [] }, "phat_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "EmployeesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employees.", "label": "Employees [Member]", "terseLabel": "Employees" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r917" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r917" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r1030" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "verboseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r917" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1027" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r917" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r917" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r917" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r917" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1029" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r970" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1023" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1023" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1023" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquipmentMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r120", "r127", "r128", "r148", "r149", "r150", "r179", "r180", "r181", "r184", "r192", "r194", "r196", "r210", "r265", "r269", "r285", "r357", "r371", "r433", "r471", "r472", "r485", "r486", "r487", "r490", "r499", "r500", "r516", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r536", "r556", "r557", "r558", "r559", "r560", "r561", "r565", "r568", "r587", "r662", "r690", "r691", "r692", "r714", "r772" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r980" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r937", "r948", "r958", "r991" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r934", "r945", "r955", "r988" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r986" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liabilities", "label": "Fair Value Adjustment of Warrants", "verboseLabel": "Fair value adjustment of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r4" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r539", "r540", "r541", "r542", "r875", "r1199", "r1202" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r539", "r540", "r541", "r542", "r875", "r1199", "r1202" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3", "terseLabel": "Fair value liability, transfers into level 3", "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r544", "r546", "r547" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "terseLabel": "Fair value liability, transfers out of level 3", "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r544", "r546", "r547" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Fair Value, Nonrecurring", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r539", "r540", "r541", "r542", "r875", "r1199" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r875", "r1196", "r1197", "r1198", "r1199", "r1200", "r1202" ] }, "phat_FinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "FinancialAssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Financial assets fair value disclosure.", "label": "Financial Assets Fair Value Disclosure", "terseLabel": "Financial assets fair value disclosure" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ForeignCountryMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Jurisdiction [Member]", "terseLabel": "Foreign", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r447", "r448" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r941", "r952", "r962", "r995" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r941", "r952", "r962", "r995" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r941", "r952", "r962", "r995" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r941", "r952", "r962", "r995" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r941", "r952", "r962", "r995" ] }, "phat_FoundersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "FoundersMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Founders.", "label": "Founders [Member]", "terseLabel": "Founders" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r975" ] }, "phat_FrazierLifeSciencesIXLimitedPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "FrazierLifeSciencesIXLimitedPartnerMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Frazier Life Sciences IX, limited partner member.", "label": "Frazier Life Sciences I X Limited Partner [Member]", "terseLabel": "Frazier" } } }, "auth_ref": [] }, "phat_FundsReceivedFromInitialClosing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "FundsReceivedFromInitialClosing", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Funds received from initial closing.", "label": "Funds Received from Initial Closing", "terseLabel": "Funds received from initial closing" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r63", "r752" ] }, "phat_GeneralAndAdministrativeExpenseRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "GeneralAndAdministrativeExpenseRelatedParty", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "documentation": "General and administrative expense related party.", "label": "General And Administrative Expense Related Party", "terseLabel": "General and administrative expenses, related party" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GranteeStatusAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r394", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GranteeStatusDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r394", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424" ] }, "phat_GrossProceedsFromRevenueInterestFinancingAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "GrossProceedsFromRevenueInterestFinancingAgreement", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross proceeds from revenue interest financing agreement.", "label": "Gross Proceeds from Revenue Interest Financing Agreement", "terseLabel": "Gross proceeds", "verboseLabel": "Proceeds from the Revenue Interest Financing Agreement" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r58", "r60", "r102", "r166", "r169", "r170", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r552", "r829", "r836", "r1115", "r1122", "r1123", "r1124", "r1125", "r1141" ] }, "us-gaap_GrossProfitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GrossProfitAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gross Profit [Abstract]" } } }, "auth_ref": [] }, "phat_HerculesLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "HerculesLoanAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Hercules loan agreement.", "label": "Hercules Loan Agreement [Member]", "terseLabel": "Hercules Loan Agreement" } } }, "auth_ref": [] }, "phat_HerculesTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "HerculesTermLoanMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Hercules Term Loan [Member]", "documentation": "Hercules Term Loan [Member]", "terseLabel": "Hercules Term Loan" } } }, "auth_ref": [] }, "stpr_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2025", "localname": "IL", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buffalo Grove, Illinois", "label": "ILLINOIS" } } }, "auth_ref": [] }, "phat_IPOAndATMOfferingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IPOAndATMOfferingsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPO And ATM Offerings", "label": "I P O and A T M Offerings [Member]", "documentation": "IPO and ATM offerings." } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IPOMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "terseLabel": "IPO", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r920", "r921", "r944" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment losses", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r4", "r75", "r876" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r77" ] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "In-Process Research and Development", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails2": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r166", "r171", "r446" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r98", "r102", "r640", "r642", "r659", "r820", "r822", "r823", "r829", "r836", "r1115", "r1122", "r1123", "r1124", "r1125" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails2": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r166", "r171", "r446" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPretaxNetLossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Total", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r102", "r664", "r829", "r902", "r903", "r1115", "r1122", "r1123", "r1124", "r1125" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r286", "r293", "r299", "r509", "r510", "r511", "r512", "r543", "r545", "r547", "r553", "r554", "r555", "r685", "r687", "r757", "r807", "r808", "r866", "r867", "r873", "r874", "r877", "r882", "r1188", "r1189", "r1229" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r293", "r299", "r509", "r510", "r511", "r512", "r543", "r545", "r547", "r553", "r554", "r555", "r685", "r687", "r757", "r807", "r808", "r866", "r867", "r873", "r874", "r877", "r882", "r1188", "r1189", "r1229" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "terseLabel": "Income Tax Authority", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r164", "r447", "r448", "r457", "r468", "r865", "r1186" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "terseLabel": "Income Tax Authority", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r164", "r447", "r448", "r457", "r468", "r865", "r1186" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r166", "r172", "r440", "r447", "r453", "r454", "r455", "r462", "r467", "r477", "r479", "r480", "r481", "r646", "r701", "r709", "r865" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Provision (benefit) for income taxes", "verboseLabel": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r105", "r116", "r166", "r195", "r196", "r209", "r230", "r251", "r445", "r447", "r478", "r665", "r820", "r822", "r823", "r865" ] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r147", "r443", "r444", "r462", "r463", "r466", "r470", "r705" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r452", "r865", "r1180" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in state rate", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r442", "r447", "r451", "r865" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes computed at the statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r447", "r865" ] }, "phat_IncomeTaxReconciliationOfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IncomeTaxReconciliationOfficersCompensation", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officers' compensation", "label": "Income Tax Reconciliation Officers Compensation", "documentation": "Income tax reconciliation officers compensation." } } }, "auth_ref": [] }, "phat_IncomeTaxReconciliationOfficersCompensationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IncomeTaxReconciliationOfficersCompensationPercent", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officers' compensation", "label": "Income Tax Reconciliation Officers Compensation Percent", "documentation": "Income tax reconciliation officers compensation percent." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r865", "r1180", "r1181" ] }, "phat_IncomeTaxReconciliationPermanentItems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IncomeTaxReconciliationPermanentItems", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation permanent items.", "label": "Income Tax Reconciliation Permanent Items", "terseLabel": "Permanent items" } } }, "auth_ref": [] }, "phat_IncomeTaxReconciliationPermanentItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IncomeTaxReconciliationPermanentItemsPercent", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUsFederalStatutoryCorporateTaxRateDetails2": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Reconciliation Permanent Items Percent", "documentation": "Income Tax Reconciliation Permanent Items Percent", "terseLabel": "Permanent items" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes, net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r450", "r865", "r1180" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Federal research and development credit", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r865", "r1180", "r1182" ] }, "phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accounts payable and accrued expenses related parties.", "label": "Increase Decrease In Accounts Payable And Accrued Expenses Related Parties", "terseLabel": "Related parties accounts payable and accrued expenses" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating right of use asset and lease liabilities.", "label": "Increase Decrease In Operating Right Of Use Asset And Lease Liabilities", "terseLabel": "Operating right-of-use assets and lease liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other long-term assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r1097" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease)in prepaid expenses and other assets related parties current.", "label": "Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current", "terseLabel": "Related parties prepaid expenses and other assets current" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r941", "r952", "r962", "r986", "r995", "r999", "r1007" ] }, "phat_InitialInvestorsAndCoFinanceLVSXXXVIILLCAndHerculesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InitialInvestorsAndCoFinanceLVSXXXVIILLCAndHerculesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Investors and CO Finance LVS XXXVII LLC and Hercules", "label": "Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member]", "documentation": "Initial investors and co finance lvs xxxvii llc and hercules." } } }, "auth_ref": [] }, "phat_InitialInvestorsNqSagardAndHerculesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InitialInvestorsNqSagardAndHerculesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial Investors NQ, Sagard, and Hercules.", "label": "Initial Investors NQ, Sagard, and Hercules [Member]", "terseLabel": "Initial Investors NQ, Sagard, and Hercules" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r1005" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r922", "r1011" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r922", "r1011" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r922", "r1011" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "totalLabel": "Interest Expense, Debt, Total", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r65", "r344", "r354", "r849", "r850", "r1260" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "totalLabel": "Interest Expense, Nonoperating, Total", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r226", "r820", "r823", "r1052" ] }, "phat_InterestExpenseRelatedToRevenueInterestFinancingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InterestExpenseRelatedToRevenueInterestFinancingLiability", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Interest expense related to revenue interest financing liability", "label": "Interest Expense Related To Revenue Interest Financing Liability", "terseLabel": "Interest expense with revenue interest finance liability", "verboseLabel": "Plus: interest expense" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity", "terseLabel": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r159", "r162", "r163" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40" ] }, "phat_InventoryCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InventoryCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total inventory", "label": "Inventory Current and Noncurrent", "documentation": "Inventory current and noncurrent." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r74", "r814" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "phat_InventoryCurrentAndNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total inventory, current", "terseLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r143", "r812", "r885" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Noncurrent", "totalLabel": "Inventory, Noncurrent, Total", "terseLabel": "Inventory, non-current", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r1037" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r106", "r133", "r142", "r270", "r271", "r273", "r603", "r824" ] }, "phat_InventoryPurchasesIncludedInAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InventoryPurchasesIncludedInAccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory purchases included in accounts payable and accrued expenses", "label": "Inventory Purchases Included In Accounts Payable And Accrued Expenses", "documentation": "Inventory purchases included in accounts payable and accrued expenses." } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1038" ] }, "phat_InventoryRawMaterialsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InventoryRawMaterialsNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "phat_InventoryCurrentAndNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Raw Materials Noncurrent", "documentation": "Inventory raw materials noncurrent.", "terseLabel": "Raw materials, non-current" } } }, "auth_ref": [] }, "us-gaap_InventoryStatedAboveCost": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryStatedAboveCost", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Stated Above Cost [true false]", "documentation": "Indicates (true false) whether inventory is stated above cost." } } }, "auth_ref": [ "r112" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory reserve", "label": "Inventory Write-down", "verboseLabel": "Inventory reserve", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r272" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "negatedLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r209", "r225", "r251", "r836", "r1051" ] }, "phat_InvestorAdditionalFundingAmountUponApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InvestorAdditionalFundingAmountUponApproval", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Investor additional funding amount upon approval.", "label": "Investor Additional Funding Amount Upon Approval", "terseLabel": "Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis" } } }, "auth_ref": [] }, "phat_InvestorsFundingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InvestorsFundingAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Investors funding amount.", "label": "Investors Funding Amount", "terseLabel": "Investors funding amount" } } }, "auth_ref": [] }, "phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Investors funding commitment potential amount available upon achievement of sales milestone.", "label": "Investors Funding Commitment Potential Amount Available Upon Achievement of Sales Milestone", "terseLabel": "Investors funding commitment potential amount available upon achievement of sales milestone" } } }, "auth_ref": [] }, "phat_InvestorsReceiptDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InvestorsReceiptDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Investors receipt description.", "label": "Investors Receipt Description", "terseLabel": "Investors receipt description" } } }, "auth_ref": [] }, "phat_InvestorsRightToReceiveRoyaltiesTerminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "InvestorsRightToReceiveRoyaltiesTerminationDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Investors right to receive royalties termination description.", "label": "Investors Right to Receive Royalties Termination Description", "terseLabel": "Investors right to receive royalties termination description" } } }, "auth_ref": [] }, "country_JE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "JE", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "JERSEY", "terseLabel": "Florham Park, New Jersey" } } }, "auth_ref": [] }, "phat_JoinderAgreementAdditionalFundingUponFdaApprovalOrDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "JoinderAgreementAdditionalFundingUponFdaApprovalOrDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joinder Agreement Additional Funding Upon FDA Approval or During the Fourth Quarter of 2023", "label": "Joinder Agreement Additional Funding Upon Fda Approval Or During the Fourth Quarter Of Two Thousand Twenty And Three [Member]", "documentation": "Joinder agreement additional funding upon fda approval or during the fourth quarter of two thousand twenty and three." } } }, "auth_ref": [] }, "phat_JoinderAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "JoinderAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joinder Agreement", "label": "Joinder Agreement [Member]", "documentation": "Joinder Agreement." } } }, "auth_ref": [] }, "phat_LanderWarrantsExpireTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LanderWarrantsExpireTerm", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lander warrants expire term.", "label": "Lander Warrants Expire Term", "terseLabel": "Warrants expire term" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r76", "r579" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "phat_LenderWarrantsExercisableSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LenderWarrantsExercisableSharesOfCommonStock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lender Warrants Exercisable Shares Of Common Stock", "documentation": "Lender warrants exercisable shares of common stock.", "terseLabel": "Warrants exercisable shares of common stock" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r572", "r580" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r572", "r580" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Future Minimum Lease Payments Under Operating Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1212" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r578", "r1102", "r1108", "r1225" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r578", "r1102", "r1108", "r1225" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r578", "r1102", "r1108", "r1225" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2030", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r578", "r1102", "r1108", "r1225" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r578", "r1102", "r1108", "r1225" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r578", "r1102", "r1108", "r1225" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r578", "r1102", "r1108", "r1225" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: amount representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r578" ] }, "phat_LesseeOperatingLeaseNumberOfOptionToExtend": { "xbrltype": "integerItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LesseeOperatingLeaseNumberOfOptionToExtend", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease number of option to extend.", "label": "Lessee Operating Lease Number Of Option To Extend", "terseLabel": "Operating lease number of option to extend" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease, option to extend description", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r573" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Operating leases, remaining lease terms", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r580", "r1210" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease, renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1211" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitments" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease Commitments", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r567" ] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r111", "r113", "r114", "r581" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r39", "r40", "r41", "r44", "r45", "r46", "r47", "r166", "r169", "r170", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r504", "r507", "r508", "r552", "r729", "r828", "r851", "r915", "r1141", "r1215", "r1216" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r54", "r97", "r654", "r885", "r902", "r903", "r1101", "r1105", "r1130", "r1203" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r41", "r132", "r166", "r169", "r170", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r504", "r507", "r508", "r552", "r885", "r1141", "r1215", "r1216" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "phat_LiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LiabilitiesLesseeAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Liabilities, lessee.", "label": "Liabilities Lessee [Abstract]", "terseLabel": "Liabilities:" } } }, "auth_ref": [] }, "phat_LicenseAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LicenseAgreementDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement description.", "label": "License Agreement Description", "terseLabel": "License agreement description" } } }, "auth_ref": [] }, "phat_LicenseAgreementTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LicenseAgreementTransactionCosts", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement transaction costs.", "label": "License Agreement Transaction Costs", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "phat_LiquidityAndCapitalResourcesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LiquidityAndCapitalResourcesPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Liquidity and capital resources.", "label": "Liquidity And Capital Resources Policy [Text Block]", "terseLabel": "Liquidity and Capital Resources" } } }, "auth_ref": [] }, "phat_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LoanAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Loan agreement.", "label": "Loan Agreement [Member]", "terseLabel": "Loan Agreement" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Total debt, net of debt discount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r12", "r95", "r167", "r178", "r337", "r352", "r644", "r847", "r848", "r883", "r1226" ] }, "phat_LongTermDebtAndInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LongTermDebtAndInterest", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt and interest.", "label": "Long Term Debt And Interest", "totalLabel": "Total principal and interest payments" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Long-term Debt, Current Maturities, Total", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "verboseLabel": "Long-term debt, current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r139" ] }, "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "phat_LongTermDebtAndInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt maturities repayments of principal and interest, year one.", "label": "Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months", "terseLabel": "2026 (final payment fee on first term loan advance)" } } }, "auth_ref": [] }, "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "phat_LongTermDebtAndInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt maturities repayments of principal and interest in year two.", "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Two", "terseLabel": "2027" } } }, "auth_ref": [] }, "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021", "label": "Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year", "documentation": "Long term debt maturities repayments of principal and interest remainder of fiscal year." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Long-term Debt, Excluding Current Maturities, Total", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of discount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r141" ] }, "phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt noncurrent excluding unamortized debt discount.", "label": "Long Term Debt Noncurrent Excluding Unamortized Debt Discount", "terseLabel": "Long-term debt, non-current portion" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r12", "r1132", "r1133", "r1134" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r12", "r28", "r1132", "r1133", "r1134" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and Equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MajorCustomersAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r259", "r853", "r856", "r895", "r900", "r1228", "r1230", "r1231", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and marketing costs", "label": "Marketing and Advertising Expense", "totalLabel": "Marketing and Advertising Expense, Total", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": [ "r63", "r822" ] }, "phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.", "label": "Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales", "terseLabel": "Maximum amount payable in sales milestones upon achievement of specified levels of product sales" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r216", "r309", "r310", "r311", "r312", "r392", "r421", "r422", "r423", "r437", "r542", "r602", "r684", "r686", "r700", "r721", "r722", "r778", "r780", "r782", "r783", "r785", "r788", "r789", "r791", "r792", "r805", "r806", "r844", "r852", "r861", "r866", "r868", "r869", "r878", "r879", "r880", "r881", "r896", "r1143", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r978" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r978" ] }, "phat_MinimumCashBalanceConditionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumCashBalanceConditionOneMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum Cash Balance Condition One.", "label": "Minimum Cash Balance Condition One [Member]", "documentation": "Minimum Cash Balance Condition One [Member]" } } }, "auth_ref": [] }, "phat_MinimumCashBalanceConditionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumCashBalanceConditionTwoMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Balance Condition Two [Member]", "documentation": "Minimum cash balance condition two.", "terseLabel": "Minimum Cash Balance Condition Two" } } }, "auth_ref": [] }, "phat_MinimumCashRequirement100PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumCashRequirement100PercentMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum Cash Requirement (100%)", "label": "Minimum Cash Requirement 100 Percent [Member]", "documentation": "Minimum cash requirement 100 percent." } } }, "auth_ref": [] }, "phat_MinimumCashRequirement30MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumCashRequirement30MillionMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Requirement 30 Million [Member]", "documentation": "Minimum cash requirement 30 million.", "terseLabel": "Minimum Cash Requirement" } } }, "auth_ref": [] }, "phat_MinimumCashRequirement50PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumCashRequirement50PercentMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum Cash Requirement (50%)", "label": "Minimum Cash Requirement 50 Percent [Member]", "documentation": "Minimum cash requirement 50 percent." } } }, "auth_ref": [] }, "phat_MinimumCashRequirement75PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumCashRequirement75PercentMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Requirement 75 Percent [Member]", "documentation": "Minimum cash requirement 75 percent.", "terseLabel": "Minimum Cash Requirement (75%)" } } }, "auth_ref": [] }, "phat_MinimumMarketCapitalizationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumMarketCapitalizationAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum market capitalization amount", "label": "Minimum Market Capitalization Amount", "documentation": "Minimum market capitalization amount." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r216", "r309", "r310", "r311", "r312", "r392", "r421", "r422", "r423", "r437", "r542", "r602", "r684", "r686", "r700", "r721", "r722", "r778", "r780", "r782", "r783", "r785", "r788", "r789", "r791", "r792", "r805", "r806", "r844", "r852", "r861", "r866", "r868", "r869", "r878", "r879", "r880", "r896", "r1143", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222" ] }, "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum percentage of qualified cash following third performance milestone", "label": "Minimum Percentage of Qualified Cash on Principal Amount Following Third Performance Milestone", "documentation": "Minimum percentage of qualified cash on principal amount following third performance milestone." } } }, "auth_ref": [] }, "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of qualified cash prior to Third performance milestone", "label": "Minimum Percentage of Qualified Cash on Principal Amount Prior to Third Performance Milestone", "documentation": "Minimum percentage of qualified cash on principal amount prior to third performance milestone." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r998" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1006" ] }, "stpr_NJ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2025", "localname": "NJ", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "NEW JERSEY", "terseLabel": "Florham Park, New Jersey" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r259", "r853", "r856", "r895", "r900", "r1228", "r1230", "r1231", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r979" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r161" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r161" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r70", "r71", "r72" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r61", "r72", "r99", "r128", "r130", "r145", "r146", "r150", "r166", "r169", "r170", "r175", "r183", "r188", "r189", "r190", "r191", "r192", "r195", "r196", "r202", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r358", "r361", "r363", "r367", "r433", "r489", "r500", "r538", "r552", "r661", "r750", "r770", "r771", "r820", "r822", "r823", "r913", "r1141" ] }, "phat_NetProceedsAfterDeductingUnderwritersCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NetProceedsAfterDeductingUnderwritersCommission", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Net proceeds after deducting underwriters commission.", "label": "Net Proceeds After Deducting Underwriters Commission", "terseLabel": "Net proceeds after deducting underwriters commission" } } }, "auth_ref": [] }, "phat_NetProceedsFromRevenueInterestFinancingTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NetProceedsFromRevenueInterestFinancingTransaction", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Net proceeds from revenue interest financing transaction.", "label": "Net Proceeds From Revenue Interest Financing Transaction", "terseLabel": "Net proceeds", "verboseLabel": "Net proceeds from revenue interest financing transaction" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "phat_NonCashFinalInterestPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NonCashFinalInterestPaymentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Non cash final interest payment fee.", "label": "Non Cash Final Interest Payment Fee", "terseLabel": "Final interest payment fee" } } }, "auth_ref": [] }, "phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "NonCash settlement of defined contribution plan liability in common stock.", "terseLabel": "Settlement of 401(k) liability in common stock", "label": "Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock" } } }, "auth_ref": [] }, "phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "NonCash settlement of employee stock purchase plan liability in common stock.", "terseLabel": "Settlement of ESPP liability in common stock", "label": "Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r978" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r941", "r952", "r962", "r986", "r995" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r969" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r968" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r986" ] }, "phat_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NonRule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arr Modified Flag", "documentation": "Non-rule 10b5-1 Arr modified flag.", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1006" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1006" ] }, "phat_NonfinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NonfinancialAssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-financial assets fair value disclosure", "label": "Nonfinancial Assets Fair Value Disclosure", "documentation": "Nonfinancial assets fair value disclosure." } } }, "auth_ref": [] }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonfinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Nonfinancial Liabilities Fair Value Disclosure, Total", "label": "Nonfinancial Liabilities Fair Value Disclosure", "terseLabel": "Non-financial liabilities fair value disclosure", "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities." } } }, "auth_ref": [ "r1196", "r1197", "r1201" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Total other income (expense)", "totalLabel": "Total other expense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r64" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income:", "verboseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "phat_NumberOfCustomersAccountedForAccountsReceivable": { "xbrltype": "integerItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NumberOfCustomersAccountedForAccountsReceivable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of customers accounted for accounts receivable", "label": "Number Of Customers Accounted For Accounts Receivable", "documentation": "Number of customers accounted for accounts receivable.." } } }, "auth_ref": [] }, "phat_NumberOfCustomersAccountedForProductSales": { "xbrltype": "integerItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NumberOfCustomersAccountedForProductSales", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of customers accounted for product sales", "label": "Number Of Customers Accounted For Product Sales", "documentation": "Number of customers accounted for product sales." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segment", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r837", "r1121" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segment", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r830", "r842", "r1121" ] }, "phat_NumberOfWarrantsRemainingExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "NumberOfWarrantsRemainingExercisable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants remaining exercisable.", "label": "Number of Warrants Remaining Exercisable", "terseLabel": "Number of warrants remaining exercisable" } } }, "auth_ref": [] }, "phat_OpenMarketSaleAgreementWithJefferiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "OpenMarketSaleAgreementWithJefferiesLLCMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Open Market Sale Agreement with Jefferies LLC.", "label": "Open Market Sale Agreement With Jefferies L L C [Member]", "terseLabel": "Open Market Sale Agreement with Jefferies LLC" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense related to services", "label": "Operating Costs and Expenses", "totalLabel": "Operating Costs and Expenses, Total", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r823" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "verboseLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r102", "r820", "r823", "r829", "r1115", "r1122", "r1123", "r1124", "r1125" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating leases, rent expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1209" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liabilities", "terseLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r570" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current", "negatedLabel": "Less: operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r570" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r570" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash payments for operating lease costs", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r571", "r575" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r569" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average incremental borrowing rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r577", "r884" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r576", "r884" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards", "totalLabel": "Operating Loss Carryforwards, Total", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r469" ] }, "phat_OperatingLossCarryforwardsExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "OperatingLossCarryforwardsExpirationYear", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards expiration year", "label": "Operating Loss Carryforwards Expiration Year", "documentation": "Operating loss carryforwards expiration year." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r469" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": [ "r469" ] }, "phat_OrganizationAndBasisOfPresentationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "OrganizationAndBasisOfPresentationPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Organization and Basis of Presentation [Policy Text Block]", "documentation": "Organization and basis of presentation.", "terseLabel": "Organization and Basis of Presentation" } } }, "auth_ref": [] }, "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Organization basis of presentation and summary of significant accounting policies.", "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Organization basis of presentation and summary of significant accounting policies.", "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]", "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization, Basis of Presentation and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r92", "r1035", "r1100" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r40" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Noncurrent, Total", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r137" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r40", "r885" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Other Liabilities, Noncurrent, Total", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r45" ] }, "phat_OtherLongTermAssetsPolicyTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "OtherLongTermAssetsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-Term Assets", "label": "Other Long-Term Assets Policy Text Block", "documentation": "Other Long-Term Assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "totalLabel": "Other Noncash Income (Expense), Total", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r72" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "terseLabel": "Other expense, net", "negatedLabel": "Other expense, net", "verboseLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r66", "r872" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r978" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r939", "r950", "r960", "r993" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r942", "r953", "r963", "r996" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r942", "r953", "r963", "r996" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "terseLabel": "Underwritten Public Offering", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "phat_PCIPharmaServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PCIPharmaServicesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "PCI Pharma Services.", "label": "P C I Pharma Services [Member]", "terseLabel": "PCI Pharma Services" } } }, "auth_ref": [] }, "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PartnerTypeOfPartnersCapitalAccountAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Partner Type [Axis]", "terseLabel": "Partner Type", "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests." } } }, "auth_ref": [ "r85", "r716" ] }, "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Partner Type of Partners' Capital Account, Name [Domain]", "terseLabel": "Partner Type of Partners' Capital Account, Name", "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests." } } }, "auth_ref": [ "r85", "r716" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r967" ] }, "phat_PaymentForFacilityCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PaymentForFacilityCharge", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for facility charge", "label": "Payment for Facility Charge", "documentation": "Payment for facility charge." } } }, "auth_ref": [] }, "phat_PaymentForLicenseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PaymentForLicenseAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment for license amount.", "label": "Payment For License Amount", "terseLabel": "Cash consideration paid for license" } } }, "auth_ref": [] }, "phat_PaymentInKindPikInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PaymentInKindPikInterestRateMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment In Kind PIK Interest Rate", "label": "Payment in Kind PIK Interest Rate [Member]", "documentation": "Payment in kind PIK interest rate." } } }, "auth_ref": [] }, "phat_PaymentOfEmployeeTaxObligationsRelatedToVestingOfPerformanceStockUnitsAndRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PaymentOfEmployeeTaxObligationsRelatedToVestingOfPerformanceStockUnitsAndRestrictedStockUnits", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of employee tax obligations related to vesting of PSUs and RSUs", "label": "Payment Of Employee Tax Obligations Related To Vesting Of Performance Stock Units And Restricted Stock Units", "documentation": "Payment of employee tax obligations related to vesting of performance stock units and restricted stock units." } } }, "auth_ref": [] }, "phat_PaymentOfTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PaymentOfTransactionCosts", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: transaction costs", "documentation": "Payment of transaction costs.", "label": "Payment of Transaction Costs", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForRepurchaseOfWarrants", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Warrants", "terseLabel": "Aggregate repurchase price of warrants", "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt." } } }, "auth_ref": [ "r68" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "negatedLabel": "Cash paid", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r298", "r1096" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Stock issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Cash paid for property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r67" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r977" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r977" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r969" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r986" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r979" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r968" ] }, "phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of aggregate payments on investment amount to investors on net sales.", "label": "Percentage Of Aggregate Payments On Investment Amount To Investors On Net Sales", "terseLabel": "Percentage of aggregate payments on investment amount to investors on net sales" } } }, "auth_ref": [] }, "phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of aggregate payments on investment amount to investors.", "label": "Percentage Of Aggregate Payments On Investment Amount To Investors", "terseLabel": "Percentage of aggregate payment on investment amount to investors" } } }, "auth_ref": [] }, "phat_PercentageOfCashInterestUponAchievingMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PercentageOfCashInterestUponAchievingMilestone", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of cash interest upon achieving milestone", "documentation": "Percentage of cash interest upon achieving milestone.", "terseLabel": "Percentage of cash interest upon achieving milestone" } } }, "auth_ref": [] }, "phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of debt funded to be issued as warrants to purchase common stock", "label": "Percentage of Debt Funded to be Issued as Warrants to Purchase Common Stock", "documentation": "Percentage of debt funded to be issued as warrants to purchase common stock." } } }, "auth_ref": [] }, "phat_PercentageOfInvestorShareOfRoyaltyInNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PercentageOfInvestorShareOfRoyaltyInNetSales", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of investor share of royalty in net sales.", "label": "Percentage of Investor Share of Royalty in Net Sales", "terseLabel": "Percentage of investor share of royalty in net sales" } } }, "auth_ref": [] }, "phat_PercentageOfTotalRevenueRepresentedByProduct": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PercentageOfTotalRevenueRepresentedByProduct", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of total revenue represented by product", "label": "Percentage Of Total Revenue Represented By Product", "documentation": "Percentage of total revenue represented by product." } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PerformanceSharesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "terseLabel": "Performance-Based Stock Units (PSU)", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r970" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1026" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r969" ] }, "phat_PotentialAdditionalInvestorFundingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PotentialAdditionalInvestorFundingAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Potential additional investor funding amount.", "label": "Potential Additional Investor Funding Amount", "terseLabel": "Potential additional investor funding amount" } } }, "auth_ref": [] }, "phat_PreFundedWarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PreFundedWarrantsPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants Policy [Policy Text Block]", "documentation": "Pre-Funded Warrants.", "terseLabel": "Pre-funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r48", "r368" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized shares", "verboseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r48", "r731" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "totalLabel": "Preferred Stock, Shares Issued, Total", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued shares", "verboseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r48", "r368" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding shares", "verboseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r48", "r731", "r749", "r1261", "r1262" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.0001 par value authorized shares 40,000,000 at December 31, 2020 and 2019 no shares issued and outstanding at December 31, 2020 and 2019", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "totalLabel": "Preferred Stock, Value, Issued, Total", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r48", "r360", "r365", "r651", "r885" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid Expense and Other Assets, Current, Total", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1039" ] }, "phat_PrepaidLeasePaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PrepaidLeasePaymentsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepaid lease payments.", "label": "Prepaid Lease Payments [Member]", "terseLabel": "Prepaid Lease Payments" } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrimeRateMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "terseLabel": "Prime Rate", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [ "r1040", "r1140" ] }, "us-gaap_PrincipalOwnerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrincipalOwnerMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Principal Owner [Member]", "terseLabel": "Frazier", "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity." } } }, "auth_ref": [] }, "phat_PriorToThreeMonthsTrailingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PriorToThreeMonthsTrailingMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior to Three Months Trailing", "label": "Prior to Three Months Trailing [Member]", "documentation": "Prior to Three Months Trailing." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offering, net of issuance costs", "verboseLabel": "Proceeds from Initial Public Offering (IPO)", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r2" ] }, "phat_ProceedsFromIssuanceInitialPublicOfferingGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ProceedsFromIssuanceInitialPublicOfferingGross", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance initial public offering gross.", "label": "Proceeds From Issuance Initial Public Offering Gross", "terseLabel": "Proceeds from issuance initial public offering gross" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of shares", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "phat_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantGross", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock and Pre-funded Warrant Gross", "documentation": "Proceeds from issuance of common stock and pre-funded warrant gross.", "terseLabel": "Proceeds from issuance of common stock and pre-funded warrant gross" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of debt", "totalLabel": "Proceeds from Issuance of Long-term Debt, Total", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r13", "r706" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of pre-funded warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "phat_ProceedsFromIssuanceUnderwrittenPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ProceedsFromIssuanceUnderwrittenPublicOffering", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from underwritten public offering", "label": "Proceeds From Issuance Underwritten Public Offering", "documentation": "Proceeds from issuance underwritten public offering." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from remaining line of credit", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r11" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r255", "r604", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r809", "r819", "r822", "r823", "r853", "r854", "r894", "r896", "r897", "r901", "r904", "r1033", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1091", "r1092", "r1093", "r1094", "r1138", "r1139", "r1228", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r255", "r604", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r809", "r819", "r822", "r823", "r853", "r854", "r894", "r896", "r897", "r901", "r904", "r1033", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1091", "r1092", "r1093", "r1094", "r1138", "r1139", "r1228", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r128", "r130", "r145", "r146", "r160", "r166", "r169", "r170", "r175", "r183", "r192", "r195", "r196", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r358", "r433", "r489", "r500", "r502", "r505", "r506", "r538", "r552", "r640", "r642", "r660", "r713", "r750", "r770", "r771", "r870", "r871", "r914", "r1050", "r1141" ] }, "phat_ProformaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ProformaRevenue", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected net revenue", "label": "Proforma Revenue", "documentation": "Proforma revenue" } } }, "auth_ref": [] }, "phat_ProjectedRevenueInTwoThousandTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ProjectedRevenueInTwoThousandTwentySevenMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Projected Revenue in Two Thousand Twenty Seven [Member]", "documentation": "Projected revenue in two thousand twenty seven,", "terseLabel": "Projected Revenue in 2027" } } }, "auth_ref": [] }, "phat_ProjectedRevenuesInTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ProjectedRevenuesInTwoThousandTwentySixMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Projected Revenues In Two Thousand Twenty Six [Member]", "documentation": "Projected revenues in two thousand twenty six.", "terseLabel": "Projected Revenue in 2026" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r579" ] }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentDisposals", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Disposals", "terseLabel": "Disposal of property, plant or equipment", "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r76", "r135", "r658" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r579" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "label": "Property, Plant and Equipment, Net", "totalLabel": "Total property, plant and equipment, net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r579", "r645", "r658", "r885" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant, and Equipment, Net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r110", "r115", "r656" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r76", "r579" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "phat_PurchaseCommitmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PurchaseCommitmentExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase commitment, expense.", "label": "Purchase Commitment Expense", "terseLabel": "Expenses incurred related to purchase commitments" } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum purchase obligation", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": [ "r46", "r96" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Purchase Obligation, Total", "label": "Purchase Obligation", "terseLabel": "Minimum purchase obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [ "r1102", "r1108", "r1225" ] }, "phat_PurchaseObligationDueInFirstTwentyFourMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PurchaseObligationDueInFirstTwentyFourMonths", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase obligation due in first twenty four months.", "label": "Purchase Obligation Due In First Twenty Four Months", "terseLabel": "Purchase obligation in the first 24-month period" } } }, "auth_ref": [] }, "phat_PurchaseOfAdditionalOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "PurchaseOfAdditionalOfferingExpenses", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of additional offering expenses.", "label": "Purchase Of Additional Offering Expenses", "terseLabel": "Purchase of additional offering expenses" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r967" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r967" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r216", "r309", "r310", "r311", "r312", "r388", "r392", "r421", "r422", "r423", "r430", "r437", "r542", "r599", "r600", "r602", "r684", "r686", "r700", "r721", "r722", "r778", "r780", "r782", "r783", "r785", "r788", "r789", "r791", "r792", "r805", "r806", "r844", "r852", "r861", "r866", "r868", "r869", "r878", "r879", "r880", "r881", "r896", "r907", "r1135", "r1143", "r1199", "r1218", "r1219", "r1220", "r1221", "r1222" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r216", "r309", "r310", "r311", "r312", "r388", "r392", "r421", "r422", "r423", "r430", "r437", "r542", "r599", "r600", "r602", "r684", "r686", "r700", "r721", "r722", "r778", "r780", "r782", "r783", "r785", "r788", "r789", "r791", "r792", "r805", "r806", "r844", "r852", "r861", "r866", "r868", "r869", "r878", "r879", "r880", "r881", "r896", "r907", "r1135", "r1143", "r1199", "r1218", "r1219", "r1220", "r1221", "r1222" ] }, "phat_RebatesReturnsAndCo-PayAssistanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RebatesReturnsAndCo-PayAssistanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Rebates, Returns and Co-Pay Assistance [Member]", "documentation": "Rebates, returns and co-pay assistance.", "terseLabel": "Rebates, Returns and Co-Pay Assistance" } } }, "auth_ref": [] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Receivables, Net, Current", "totalLabel": "Receivables, Net, Current, Total", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r885" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r934", "r945", "r955", "r988" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "terseLabel": "Related Party", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r166", "r174", "r175", "r262", "r389", "r390", "r591", "r592", "r649", "r655", "r724", "r725", "r726", "r727", "r728", "r748", "r777", "r1259" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r166", "r174", "r175", "r591", "r592", "r593", "r594", "r649", "r655", "r724", "r725", "r726", "r727", "r728", "r748", "r777" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r166", "r174", "r175", "r591", "r592", "r1214" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction", "documentation": "Transaction between related party." } } }, "auth_ref": [ "r166", "r174", "r175", "r1214" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r166", "r174", "r175", "r262", "r591", "r592", "r594", "r753", "r754", "r757" ] }, "phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Related party transaction shared operating expenses due to transactions with related party.", "label": "Related Party Transaction Shared Operating Expenses Due To Transactions With Related Party", "verboseLabel": "Shared operating expenses" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r166", "r174", "r175", "r262", "r389", "r390", "r591", "r592", "r649", "r655", "r724", "r725", "r726", "r727", "r728", "r748", "r777", "r1214", "r1259" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r588", "r589", "r590", "r592", "r595", "r710", "r711", "r712", "r755", "r756", "r757", "r775", "r776" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Final payment of debt", "label": "Repayments of Debt", "terseLabel": "Final payment of debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1095" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt amount repaid", "label": "Repayments of Long-Term Debt", "totalLabel": "Repayments of Long-Term Debt, Total", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r69", "r707" ] }, "us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReportableSegmentAggregationBeforeOtherOperatingSegmentMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Reportable Segment, Aggregation before Other Operating Segment [Member]", "terseLabel": "Reportable Segment, Aggregation before Other Operating Segment", "documentation": "Aggregation of reportable segments before other operating segment. Excludes intersegment elimination and reconciling item." } } }, "auth_ref": [ "r836", "r837" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r166", "r176", "r177", "r328", "r369", "r594", "r601", "r647", "r815", "r816", "r817", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1190", "r1191", "r1192", "r1193" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "verboseLabel": "Research and development", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r439", "r807", "r820", "r821", "r836", "r1223" ] }, "phat_ResearchAndDevelopmentExpenseExcludingStockBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ResearchAndDevelopmentExpenseExcludingStockBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research and development expense excluding stock based compensation expense", "documentation": "Research and development expense excluding stock-based compensation expense.", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses and Accruals", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r438" ] }, "phat_ResearchAndDevelopmentExpenseRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ResearchAndDevelopmentExpenseRelatedParty", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Research and development expense related party.", "label": "Research And Development Expense Related Party", "terseLabel": "Research and development expenses, related party" } } }, "auth_ref": [] }, "phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Research and development tax credit carry forward expiration year.", "label": "Research And Development Tax Credit Carry Forward Expiration Year", "terseLabel": "Research and development credits expiration period" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r935", "r946", "r956", "r989" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r936", "r947", "r957", "r990" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r943", "r954", "r964", "r997" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash, Total", "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1036", "r1099", "r1224", "r1227" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r1114", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuring1" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r295", "r296", "r298", "r301", "r306" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring expenses incurred", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r297", "r300", "r303", "r305" ] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Reduction in number of employees on restructuring", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percentage of reduction in number of employees on restructuring", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Total restructuring charges", "totalLabel": "Balance as of June 30, 2025", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r4", "r153", "r154", "r302", "r303", "r821", "r1136" ] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringChargesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring Charges [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r153", "r154", "r297", "r298", "r303", "r304", "r821" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r303", "r304", "r305" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringCosts", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Costs", "totalLabel": "Restructuring Costs, Total", "terseLabel": "Restructuring charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r1031", "r1032" ] }, "phat_RestructuringNon-CashExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RestructuringNon-CashExpenses", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash expenses", "label": "Restructuring Non-cash Expenses", "documentation": "Restructuring non-cash expenses." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve", "periodStartLabel": "Restructuring Reserve, Beginning Balance", "totalLabel": "Restructuring Reserve, Total", "terseLabel": "Restructuring related accruals", "periodEndLabel": "Balance as of December 31, 2025", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r298", "r304" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r51", "r84", "r653", "r694", "r699", "r708", "r732", "r885" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r120", "r127", "r128", "r179", "r180", "r181", "r184", "r192", "r194", "r196", "r265", "r269", "r285", "r357", "r433", "r471", "r472", "r485", "r486", "r487", "r490", "r499", "r500", "r516", "r519", "r520", "r523", "r536", "r565", "r568", "r690", "r692", "r714", "r1261" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "phat_RevenueFromContractWithCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueFromContractWithCustomerLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Line Items]", "documentation": "Revenue from contract with customer." } } }, "auth_ref": [] }, "phat_RevenueFromContractWithCustomerTable": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueFromContractWithCustomerTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Table]", "documentation": "Revenue from contract with customer." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognition" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r117", "r375", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r385", "r387" ] }, "phat_RevenueInterestFinancingAgreementFundingCommitmentOnDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementFundingCommitmentOnDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Interest Financing Agreement Funding Commitment On During the Fourth Quarter Of Two Thousand Twenty And Three [Member]", "documentation": "Revenue interest financing agreement funding commitment on during the fourth quarter of two thousand twenty and three.", "terseLabel": "Revenue Interest Financing Agreement Funding Commitment On During the Fourth Quarter of 2023" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement funding commitment on or before March thirty one two thousand and twenty four.", "label": "Revenue Interest Financing Agreement Funding Commitment On Or Before March Thirty One Two Thousand And Twenty Four [Member]", "terseLabel": "Revenue Interest Financing Agreement, Funding Commitment On or Before March 31, 2024" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue \u200binterest\u200b financing\u200b agreement\u200b funding upon achievement of sales milestone at any time prior to June thirty two thousand and twenty four.", "label": "Revenue Interest Financing Agreement Funding Upon Achievement of Sales Milestone At Any Time prior To June Thirty Two Thousand and Twenty Four [Member]", "terseLabel": "Revenue Interest Financing Agreement Funding upon Achievement of Sales Milestone at any Time Prior to June 30, 2024" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue \u200binterest\u200b financing\u200b agreement\u200b funding upon FDA approval at any time prior to December thirty one two thousand and twenty two.", "label": "Revenue Interest Financing Agreement Funding Upon FDA Approval At Any Time prior To December Thirty One Two Thousand and Twenty Two [Member]", "terseLabel": "Revenue Interest Financing Agreement Funding upon FDA Approval at any Time Prior to December 31, 2022" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue Interest Financing Agreement [Member]", "label": "Revenue Interest Financing Agreement [Member]", "terseLabel": "Revenue Interest Financing Agreement" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement percentage on investment amount On December thirty one two thousand and thirty seven.", "label": "Revenue Interest Financing Agreement Percentage On Investment Amount On December Thirty One Two Thousand And Thirty Seven [Member]", "terseLabel": "Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement percentage on investment amount on December thirty one two thousand and twenty eight.", "label": "Revenue Interest Financing Agreement Percentage on Investment Amount On December Thirty One Two Thousand And Twenty Eight [Member]", "terseLabel": "Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is thereafter to May three two thousand and twenty three.", "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA approval If occurrence is Thereafter to May Three Two Thousand and Twenty Three [Member]", "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA approval If occurrence is Thereafter to May 3, 2023" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is prior to May three two thousand and twenty three.", "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval If Occurrence Prior to May Three Two Thousand and Twenty Three [Member]", "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement upon occurrence of a Change in control event earlier of April one two thousand and twenty four or FDA Approval.", "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval [Member]", "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement upon occurrence of event of default after April one two thousand and twenty eight.", "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default After April One Two Thousand and Twenty Eight [Member]", "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement upon occurrence of event between April one two thousand and twenty five and April one two thousand and twenty eight.", "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default Between April One Two Thousand and Twenty Five and April One Two Thousand and Twenty Eight [Member]", "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement upon occurrence of event of default prior to April one two thousand and twenty five.", "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default prior to April One Two thousand and Twenty Five [Member]", "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingLiability", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing liability.", "label": "Revenue Interest Financing Liability", "terseLabel": "Revenue interest financing liability", "periodEndLabel": "Ending liability balance", "periodStartLabel": "Beginning liability balance" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingLiabilityEffectiveInterestRate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue interest financing liability effective interest rate", "documentation": "Revenue interest financing liability effective interest rate.", "terseLabel": "Revenue interest financing liability, effective interest rate" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Long-term liability ending balance", "documentation": "Revenue interest financing liability noncurrent.", "label": "Revenue Interest Financing Liability Noncurrent", "terseLabel": "Revenue interest financing liability", "negatedLabel": "Less: current portion" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingLiabilityPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing liability.", "label": "Revenue Interest Financing Liability [Policy Text Block]", "terseLabel": "Revenue Interest Financing Liability" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestFinancingLiabilityTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiability" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing liability.", "label": "Revenue Interest Financing Liability [Text Block]", "terseLabel": "Revenue Interest Financing Liability" } } }, "auth_ref": [] }, "phat_RevenueInterestLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RevenueInterestLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: current portion", "label": "Revenue Interest Liability Current", "documentation": "Revenue interest liability current." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r751" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product revenue, net", "terseLabel": "Net product revenues related to sales", "totalLabel": "Revenues, Total", "verboseLabel": "Product revenue, net", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r100", "r101", "r151", "r166", "r169", "r170", "r209", "r223", "r224", "r245", "r251", "r255", "r257", "r259", "r263", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r552", "r640", "r642", "r836", "r872", "r902", "r903", "r1141" ] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r62" ] }, "phat_RoyaltyPaymentsAndPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "RoyaltyPaymentsAndPayables", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: royalty payments and payables", "label": "Royalty Payments and Payables", "documentation": "Royalty payments and payables.", "terseLabel": "Less: royalty payments and payables" } } }, "auth_ref": [] }, "phat_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "Rule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arr Modified Flag", "documentation": "Rule 10b5-1 Arr modified flag.", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1006" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1006" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SalesRevenueProductLineMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Sales", "label": "Revenue, Product and Service Benchmark [Member]", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r1117", "r1118" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r12", "r30", "r31", "r36", "r82", "r83", "r847", "r849", "r1102", "r1108", "r1206", "r1225" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Components of Deferred Tax Assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1185" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r449", "r865", "r1180" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income Pre Tax Net Loss From Operations", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1101", "r1106" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r5", "r55", "r56", "r57" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Future Minimum Principal Payments Under Term Loans", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "terseLabel": "Summary of PSU Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": [ "r88" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r579" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r166", "r174", "r175", "r591", "r592", "r594", "r753", "r754", "r757" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r303", "r304", "r305" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Activity Related to Restructuring Accrual", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r27", "r78", "r79" ] }, "phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of revenue interest financing liability.", "label": "Schedule of Revenue Interest Financing Liability [Table Text Block]", "terseLabel": "Schedule of Total Revenue Interest Financing Liability" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r22", "r23", "r24" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Financial Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r22", "r23", "r24" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r394", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r430" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r87" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r91", "r1177" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Summary of Activity Related to Gross Unrecognized Benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r458", "r864" ] }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "terseLabel": "Summary of Unvested Shares", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": [ "r1158" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r916" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r919" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r100", "r101", "r102", "r103", "r209", "r218", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r237", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r253", "r259", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r300", "r305", "r494", "r495", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r832", "r836", "r837", "r845", "r899", "r1228", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "auth_ref": [ "r213", "r257", "r258", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r641", "r642", "r643", "r718", "r719", "r720", "r779", "r781", "r784", "r786", "r788", "r790", "r791", "r792", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r810", "r826", "r853", "r855", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r898", "r907", "r1228", "r1230", "r1231", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r221", "r835", "r843" ] }, "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description", "terseLabel": "Segment reporting, CODM, profit (loss) measure, how used, description", "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource." } } }, "auth_ref": [ "r244", "r832", "r840" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r103", "r209", "r217", "r218", "r219", "r220", "r222", "r234", "r236", "r237", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r259", "r830", "r833", "r834", "r836", "r838", "r841", "r842" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemCompositionDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingOtherItemCompositionDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Other Segment Item, Composition, Description", "terseLabel": "Segment reporting, other segment item, composition, description", "documentation": "Description of composition of other segment item not separately disclosed." } } }, "auth_ref": [ "r209", "r236", "r237", "r251", "r836" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r254", "r257", "r831", "r832", "r839" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "totalLabel": "Selling and Marketing Expense, Total", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "totalLabel": "Selling, General and Administrative Expense, Total", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r63", "r819", "r820", "r821", "r823", "r1090" ] }, "phat_SellingGeneralAndAdministrativeExpenseRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "SellingGeneralAndAdministrativeExpenseRelatedParty", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and administrative expenses, related party", "label": "Selling, General And Administrative Expense Related Party", "documentation": "Selling, general and administrative expense related party." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expense", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [ "r866", "r867" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r1179" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "verboseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Equity plan, description", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Units, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Number of Stock Units, Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Stock Units, Granted", "verboseLabel": "Stock awards, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Unvested Ending Balance", "periodStartLabel": "Unvested Beginning Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "PSUs outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r409", "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance", "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r409", "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Number of Stock Units, Vested", "negatedLabel": "Number of Stock Units, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Assumptions:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r394", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum percentage of eligible compensation contributed by participants", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional number of shares available for issuance", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1176" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock, shares authorized for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r863" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r34" ] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant annual increase.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase", "terseLabel": "Number of shares remain available for issuance, annual increase" } } }, "auth_ref": [] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, cancelled or forfeited", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options and Other Than Options Forfeitures and Expirations in Period", "documentation": "Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.", "verboseLabel": "Number of shares, cancelled or forfeited" } } }, "auth_ref": [] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, granted", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options and Other than Options, Grants In Period Gross", "documentation": "Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.", "verboseLabel": "Number of shares, granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Outstanding, Options exercisable as of December 31, 2025", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercisable as of December 31, 2025", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total intrinsic value of stock options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options cancelled or forfeited", "negatedLabel": "Options Outstanding, Options cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Options Outstanding, Options cancelled", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options Outstanding, Options granted", "verboseLabel": "Stock options, granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Estimated weighted-average fair value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding, Ending Balance", "periodStartLabel": "Options Outstanding, Beginning Balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r401", "r402" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r401", "r402" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest as of December 31, 2025", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options Outstanding, Options vested and expected to vest as of December 31, 2025", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options vested and expected to vest as of December 31, 2025", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Annual increase to shares available for issuance percentage of outstanding common stock", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [ "r1176" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation incremental expense", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r34" ] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options Outstanding, Options exercised", "documentation": "Share based compensation arrangement by share based payment award stock options exercised and shares vested.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested", "terseLabel": "Options Outstanding, Options exercised and shares vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424" ] }, "phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options exercised", "documentation": "Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "First Anniversary", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ShareBasedPaymentArrangementEmployeeAndNonemployeeMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement, employee and nonemployee.", "label": "Share Based Payment Arrangement Employee And Nonemployee [Member]", "terseLabel": "Employee and Nonemployee Director" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r420" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of December 31, 2025", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Options exercisable as of December 31, 2025", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r90" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Options vested and expected to vest as of December 31, 2025", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r417" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of PSUs vested", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r416" ] }, "phat_SharesIssuedPricePerShareAfterDeductions": { "xbrltype": "perShareItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "SharesIssuedPricePerShareAfterDeductions", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares issued, price per share after deductions.", "label": "Shares Issued Price Per Share After Deductions", "terseLabel": "Purchase price per share after deducting underwriting discounts and commissions" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease costs", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r574", "r884" ] }, "phat_SiliconValleyBankTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "SiliconValleyBankTermLoanMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SVB Term Loan", "label": "Silicon Valley Bank Term Loan [Member]", "documentation": "SVB term loan." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r447" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r100", "r101", "r102", "r103", "r129", "r209", "r218", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r237", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r253", "r259", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r287", "r300", "r305", "r494", "r495", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r832", "r836", "r837", "r845", "r899", "r1228", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r49", "r52", "r53", "r120", "r127", "r128", "r148", "r149", "r150", "r179", "r180", "r181", "r184", "r192", "r194", "r196", "r210", "r265", "r269", "r285", "r357", "r371", "r433", "r471", "r472", "r485", "r486", "r487", "r490", "r499", "r500", "r516", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r536", "r556", "r557", "r558", "r559", "r560", "r561", "r565", "r568", "r587", "r662", "r690", "r691", "r692", "r714", "r772" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "auth_ref": [ "r213", "r257", "r258", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r641", "r642", "r643", "r718", "r719", "r720", "r779", "r781", "r784", "r786", "r788", "r790", "r791", "r792", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r810", "r826", "r853", "r855", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r898", "r907", "r1228", "r1230", "r1231", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r179", "r180", "r181", "r210", "r359", "r360", "r362", "r364", "r568", "r604", "r704", "r715", "r717", "r723", "r724", "r725", "r726", "r727", "r728", "r731", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r744", "r745", "r746", "r747", "r748", "r751", "r752", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r772", "r822", "r823", "r908", "r1259" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionLocationActivityCapitalizationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionLocationActivityCapitalizationAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Activity, Capitalization [Axis]", "documentation": "Information by location in statement of financial position in which disaggregated capitalized activity is included." } } }, "auth_ref": [ "r1188", "r1189", "r1204" ] }, "us-gaap_StatementOfFinancialPositionLocationActivityCapitalizationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionLocationActivityCapitalizationDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Activity, Capitalization [Domain]", "documentation": "Location in statement of financial position in which disaggregated capitalized activity is included." } } }, "auth_ref": [ "r1188", "r1189", "r1204" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r179", "r180", "r181", "r210", "r262", "r359", "r360", "r362", "r364", "r568", "r604", "r704", "r715", "r717", "r723", "r724", "r725", "r726", "r727", "r728", "r731", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r744", "r745", "r746", "r747", "r748", "r751", "r752", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r772", "r822", "r823", "r908", "r1259" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r938", "r949", "r959", "r992" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP shares issued, shares", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r8", "r48", "r49", "r84" ] }, "phat_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock from exercise of warrants, shares", "documentation": "Stock issued during period shares exercise of warrants.", "verboseLabel": "Issuance of common stock warrants shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock shares issued", "verboseLabel": "Shares issued", "terseLabel": "Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r48", "r49", "r84", "r706", "r772", "r787" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted shares, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r8", "r84" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock from exercises of stock options, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r48", "r49", "r84", "r406" ] }, "phat_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Vesting Of Restricted Stock Units And Performance Stock Units, Net Of Employee Tax Obligation", "documentation": "Stock issued during period, shares, vesting of restricted stock units and performance stock units, net of employee tax obligation.", "terseLabel": "Vesting of restricted stock units and performance stock units, net of employee tax obligations, shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP shares issued", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r8", "r48", "r49", "r84" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock under ATM facility", "verboseLabel": "Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r48", "r49", "r84", "r714", "r772", "r787", "r914" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock from exercises of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r49", "r52", "r53", "r84" ] }, "phat_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Vesting Of Restricted Stock Units And Performance Stock Units, Net Of Employee Tax Obligation", "documentation": "Stock issued during period, value, vesting of restricted stock units and performance stock units, net of employee tax obligation.", "terseLabel": "Vesting of restricted stock units and performance stock units, net of employee tax obligations" } } }, "auth_ref": [] }, "phat_StockOptionAndRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockOptionAndRestrictedStockUnitMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options and RSUs", "label": "Stock Option And Restricted Stock Unit [Member]", "documentation": "Stock option and restricted stock unit member." } } }, "auth_ref": [] }, "phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock option performance-based unit and restricted stock unit.", "label": "Stock Option Performance-based Unit and Restricted Stock Unit [Member]", "terseLabel": "Stock Options, PSUs and RSUs Outstanding", "verboseLabel": "Stock Options, PSUs and RSUs Outstanding" } } }, "auth_ref": [] }, "phat_StockOptionsAndPerformanceBasedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockOptionsAndPerformanceBasedUnitsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options and Performance-based Units", "label": "Stock options and performance-based units [Member]", "documentation": "Stock options and performance-based units." } } }, "auth_ref": [] }, "phat_StockOptionsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockOptionsAndRestrictedStockUnitsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options and Restricted Stock Units [Member]", "documentation": "Stock options and restricted stock units.", "terseLabel": "Stock Options and Restricted Stock Units Outstanding" } } }, "auth_ref": [] }, "phat_StockOptionsPerformanceStockUnitsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockOptionsPerformanceStockUnitsAndRestrictedStockUnitsMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options Performance Stock Units and Restricted Stock Units [Member]", "documentation": "Stock options performance stock units and restricted stock units.", "terseLabel": "Stock Options Performance Stock Units and Restricted Stock Units", "verboseLabel": "Stock Options, RSUs nad PSUs" } } }, "auth_ref": [] }, "phat_StockRepurchaseProgramExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockRepurchaseProgramExpirationMonthAndYear", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock repurchase program expiration period", "documentation": "Stock Repurchase Program Expiration Month and Year", "terseLabel": "Stock repurchase program expiration period" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program Number of Shares Authorized to be Repurchased", "terseLabel": "Number of shares authorized to repurchase" } } }, "auth_ref": [ "r1146" ] }, "phat_StockRepurchaseProgramNumberOfSharesRightLapse": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "StockRepurchaseProgramNumberOfSharesRightLapse", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock repurchase program, number of shares right lapse.", "label": "Stock Repurchase Program Number Of Shares Right Lapse", "terseLabel": "Stock repurchase program, number of shares right lapse" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Period in Force", "terseLabel": "Stock repurchase program, period in force", "documentation": "Period share may be purchased under authorized share repurchase plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Remaining Authorized, Number of Shares", "terseLabel": "Remaining number of shares to be repurchased", "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' deficit", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r49", "r52", "r53", "r73", "r733", "r749", "r773", "r774", "r885", "r915", "r1101", "r1104", "r1105", "r1130", "r1203", "r1261" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r562", "r597" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r562", "r597" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTable", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r562", "r597" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r562", "r597" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r562", "r597" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEvents1" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r596", "r598" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of Activity Related to Gross Unrecognized Benefits", "documentation": "Tabular disclosure for tax position taken on unrecognized tax benefit." } } }, "auth_ref": [ "r104", "r1183", "r1184" ] }, "phat_SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue Allowances and Related Accruals", "label": "Summary of Revenue Allowances and Related Accruals [Table Text Block]", "documentation": "Summary of revenue allowances and related accruals." } } }, "auth_ref": [] }, "phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "documentation": "Summary of supplemental balance sheet information related to operating leases.", "label": "Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]", "terseLabel": "Summary of Supplemental Balance Sheet Information Related to the Operating Leases" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r985" ] }, "phat_TakedaLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TakedaLicenseAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Takeda license agreement.", "label": "Takeda License Agreement [Member]", "terseLabel": "Takeda License", "verboseLabel": "Takeda License Agreement" } } }, "auth_ref": [] }, "phat_TakedaPharmaceuticalCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TakedaPharmaceuticalCompanyLimitedMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Takeda pharmaceutical company limited.", "label": "Takeda Pharmaceutical Company Limited [Member]", "terseLabel": "Takeda" } } }, "auth_ref": [] }, "phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax cuts and jobs act, research and development expenditures amortization period.", "label": "Tax Cuts and Jobs Act, Research and Development Expenditures Amortization Period", "terseLabel": "Research and development expenditures, amortization period" } } }, "auth_ref": [] }, "phat_TemporaryServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TemporaryServicesAgreementMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Temporary services agreement.", "label": "Temporary Services Agreement [Member]", "terseLabel": "Temporary Services Agreement" } } }, "auth_ref": [] }, "phat_TermLoanAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Advance", "label": "Term Loan Advance [Member]", "documentation": "Term loan advance." } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentAfterFebruaryOneTwoThousandTwentyNineButOnOrPriorToJanuaryOneTwoThousandThirtyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentAfterFebruaryOneTwoThousandTwentyNineButOnOrPriorToJanuaryOneTwoThousandThirtyMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment After February One Two Thousand Twenty Nine But on or Prior to January One Two Thousand Thirty [Member]", "documentation": "Term loan advance prepayment after february one two thousand twenty nine but on or prior to january one two thousand thirty,", "terseLabel": "Term Loan Advance Prepayment after February 1, 2029 but on or prior to January 1, 2030" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentAfterFebruaryOneTwoThousandTwentyNineButOnOrPriorToJanuaryOneTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentAfterFebruaryOneTwoThousandTwentyNineButOnOrPriorToJanuaryOneTwoThousandTwentyMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment After February One Two Thousand Twenty Nine But on or Prior to January One Two Thousand Twenty [Member]", "documentation": "Term loan advance prepayment after february one two thousand twenty nine but on or prior to january one two thousand twenty,", "terseLabel": "Term Loan Advance Prepayment after February 1, 2029 but on or prior to January 1, 2020" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentAfterJanuaryOneTwoThousandThirtyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentAfterJanuaryOneTwoThousandThirtyMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment After January One Two Thousand Thirty [Member]", "documentation": "Term loan advance prepayment after january one two thousand thirty.", "terseLabel": "Term Loan Advance Prepayment after January 1, 2030" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentAfterSeptemberOneTwoThousandTwentySevenButOnOrPriorToFebruaryOneTwoThousandTwentyNineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentAfterSeptemberOneTwoThousandTwentySevenButOnOrPriorToFebruaryOneTwoThousandTwentyNineMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment After September One Two Thousand Twenty Seven But on or Prior to February One Two Thousand Twenty Nine [Member]", "documentation": "Term loan advance prepayment after september one two thousand twenty seven but on or prior to february one two thousand twenty nine.", "terseLabel": "Term Loan Advance Prepayment after September 1, 2027 but on or prior to February 1, 2029" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentOnOrAfterOctoberOneTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentOnOrAfterOctoberOneTwoThousandTwentySixMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Advance Prepayment on or after October 1, 2026", "label": "Term Loan Advance Prepayment On Or After October One Two Thousand Twenty Six [Member]", "documentation": "Term Loan Advance Prepayment On Or After October One Two Thousand Twenty Six." } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentOnOrAfterTheTwelfthMonthAnniversaryButPriorToTwenty-FourthMonthAnniversaryOfTheFifthAmendmentClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentOnOrAfterTheTwelfthMonthAnniversaryButPriorToTwenty-FourthMonthAnniversaryOfTheFifthAmendmentClosingDateMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment on or After the Twelfth Month Anniversary But Prior To Twenty-fourth Month Anniversary Of The Fifth Amendment Closing Date [Member]", "documentation": "Term loan advance prepayment on or after the twelfth month anniversary but prior to twenty-fourth month anniversary of the fifth amendment closing date.", "terseLabel": "Term Loan Advance Prepayment on or After the twelfth month anniversary but prior to the twenty-fourth month anniversary of the Fifth Amendment Closing Date" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentOnOrAfterTheTwenty-FourthMonthAnniversaryButPriorToThirty-SixthMonthAnniversaryOfTheFifthAmendmentClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentOnOrAfterTheTwenty-FourthMonthAnniversaryButPriorToThirty-SixthMonthAnniversaryOfTheFifthAmendmentClosingDateMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment on or After the Twenty-fourth Month Anniversary But Prior To Thirty-sixth Month Anniversary Of The Fifth Amendment Closing Date [Member]", "documentation": "Term loan advance prepayment on or after the twenty-fourth month anniversary but prior to thirty-sixth month anniversary of the fifth amendment closing date.", "terseLabel": "Term Loan Advance Prepayment on or After the Twenty-fourth Month Anniversary But Prior to Thirty-sixth Month Anniversary of the Fifth Amendment Closing Date" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentPriorToOctoberOneTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentPriorToOctoberOneTwoThousandTwentySixMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Advance Prepayment Prior to October 1, 2026", "label": "Term Loan Advance Prepayment Prior to October One Two Thousand Twenty Six [Member]", "documentation": "Term Loan Advance Prepayment Prior to October One Two Thousand Twenty Six [Member]" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentPriorToSeptemberTwoThousandTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentPriorToSeptemberTwoThousandTwentySevenMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Advance Prepayment Prior to September, 2027", "label": "Term Loan Advance Prepayment Prior To September Two Thousand Twenty Seven [Member]", "documentation": "Term loan advance prepayment prior to september two thousand twenty seven." } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentPriorToTwelfthMonthAnniversaryOfTheFifthAmendmentClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanAdvancePrepaymentPriorToTwelfthMonthAnniversaryOfTheFifthAmendmentClosingDateMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment Prior to twelfth month anniversary of the Fifth Amendment Closing Date [Member]", "documentation": "Term loan advance prepayment prior to twelfth month anniversary of the fifth amendment closing date.", "terseLabel": "Term Loan Advance Prepayment Prior to Twelfth Month Anniversary of the Fifth Amendment Closing Date" } } }, "auth_ref": [] }, "phat_TermLoanFirstAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanFirstAdvanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan First Advance", "label": "Term Loan First Advance [Member]", "documentation": "Term loan first advance." } } }, "auth_ref": [] }, "phat_TermLoanFourAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanFourAdvanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Four Advance", "label": "Term Loan Four Advance [Member]", "documentation": "Term Loan Four Advance." } } }, "auth_ref": [] }, "phat_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "verboseLabel": "Term Loans", "documentation": "Term loan.", "label": "Term Loan [Member]" } } }, "auth_ref": [] }, "phat_TermLoanSecondAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanSecondAdvanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Second Advance", "label": "Term Loan Second Advance [Member]", "documentation": "Term Loan Second Advance." } } }, "auth_ref": [] }, "phat_TermLoanThirdAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoanThirdAdvanceMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Third Advance [Member]", "documentation": "Term loan third advance.", "terseLabel": "Term Loan Third Advance" } } }, "auth_ref": [] }, "phat_TermLoansAggregateFiveAdditionalTranchesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregateFiveAdditionalTranchesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loans Aggregate Five Additional Tranches [Member]", "documentation": "Term Loans Aggregate Five Additional Tranches.", "terseLabel": "Term Loans Aggregate Five Additional Tranches" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalAmountTranchesFiveMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Five", "label": "Term Loans Aggregate Principal Amount Tranches Five [Member]", "documentation": "Term Loans Aggregate Principal Amount Tranches Five." } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalAmountTranchesFourMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Four", "label": "Term Loans Aggregate Principal Amount Tranches Four [Member]", "documentation": "Term loans, aggregate principal amount tranches four." } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalAmountTranchesOneMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Aggregate Principal Amount Tranches One", "label": "Term Loans Aggregate Principal Amount Tranches One [Member]", "documentation": "Term loans, aggregate principal amount tranches one." } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalAmountTranchesSixMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Six", "label": "Term Loans Aggregate Principal Amount Tranches Six [Member]", "documentation": "Term Loans Aggregate Principal Amount Tranches Six." } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Three and Four", "documentation": "Term loans aggregate principal amount tranches three and four.", "label": "Term Loans Aggregate Principal Amount Tranches Three and Four [Member]" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalAmountTranchesThreeMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Three", "label": "Term Loans Aggregate Principal Amount Tranches Three [Member]", "documentation": "Term loans, aggregate principal amount tranches three." } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalAmountTranchesTwoMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Two", "label": "Term Loans Aggregate Principal Amount Tranches Two [Member]", "documentation": "Term loans, aggregate principal amount tranches two." } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalFundedAmountTranchesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansAggregatePrincipalFundedAmountTranchesTwoMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loans Aggregate Principal Funded Amount Tranches Two [Member]", "documentation": "Term loans aggregate principal funded amount tranches two.", "terseLabel": "Term Loans, Aggregate Principal Funded Amount Tranches Two" } } }, "auth_ref": [] }, "phat_TermLoansPriorToThreeMonthsTrailingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansPriorToThreeMonthsTrailingMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Prior to Three Months Trailing", "label": "Term Loans, Prior to Three Months Trailing [Member]", "documentation": "Term Loans, Prior to Three Months Trailing." } } }, "auth_ref": [] }, "phat_TermLoansThreeMonthsTrailingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TermLoansThreeMonthsTrailingMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans, Three Months Trailing", "label": "Term Loans, Three Months Trailing [Member]", "documentation": "Term Loans, Three Months Trailing." } } }, "auth_ref": [] }, "phat_ThreeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ThreeCustomersMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Three Customers [Member]", "documentation": "Three customers.", "terseLabel": "Three Customers" } } }, "auth_ref": [] }, "phat_ThreeMonthsTrailingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "ThreeMonthsTrailingMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Months Trailing", "label": "Three Months Trailing [Member]", "documentation": "Three Months Trailing." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "terseLabel": "Title of Individual" } } }, "auth_ref": [ "r1126", "r1213" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "terseLabel": "Title of Individual" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r977" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r984" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r1127", "r1128", "r1129" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1005" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1007" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "phat_TrancheExtensionAmendmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TrancheExtensionAmendmentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tranche extension amendment fee", "documentation": "Tranche extension amendment fee", "terseLabel": "Tranche extension amendment fee" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1008" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1009" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1009" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1007" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1007" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1010" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r1008" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical", "http://www.phathompharma.com/20251231/taxonomy/role/StatementStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, shares", "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock - 19 shares at March 31, 2023 and December 31, 2022, respectively", "verboseLabel": "Treasury stock - 19 shares at September 30, 2025 and December 31, 2024", "terseLabel": "Treasury stock - 19 shares at December 31, 2025 and December 31, 2024", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32", "r33", "r52" ] }, "phat_TwoThousandNineteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TwoThousandNineteenEquityIncentivePlanMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2019 equity incentive plan.", "label": "Two Thousand Nineteen Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "auth_ref": [] }, "phat_TwoThousandNineteenIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TwoThousandNineteenIncentiveAwardPlanMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen incentive award plan.", "label": "Two Thousand Nineteen Incentive Award Plan [Member]", "terseLabel": "2019 Incentive Award Plan", "verboseLabel": "2019 Incentive Award Plan" } } }, "auth_ref": [] }, "phat_TwoThousandTwentyATMOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TwoThousandTwentyATMOfferingProgramMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 At-the-Market Offering Program", "label": "Two Thousand Twenty A T M Offering Program [Member]", "documentation": "Two thousand twenty A T M offering program." } } }, "auth_ref": [] }, "phat_TwoThousandTwentyFiveEmploymentInducementIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TwoThousandTwentyFiveEmploymentInducementIncentiveAwardPlanMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inducement Plan", "label": "Two Thousand Twenty Five Employment Inducement Incentive Award Plan [Member]", "documentation": "Two Thousand Twenty Five Employment Inducement Incentive Award Plan.", "verboseLabel": "2025 Employment Inducement Incentive Award Plan" } } }, "auth_ref": [] }, "phat_TwoThousandTwentyThreeAtmOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "TwoThousandTwentyThreeAtmOfferingProgramMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Three ATM Offering Program [Member]", "documentation": "Two thousand twenty three atm offering program.", "terseLabel": "2023 At-the-Market Offering Program" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r156", "r157", "r158", "r183", "r184", "r185", "r186", "r187", "r198", "r260", "r261", "r265", "r267", "r268", "r269", "r284", "r285", "r294", "r355", "r356", "r357", "r358", "r431", "r432", "r433", "r434", "r471", "r472", "r473", "r474", "r475", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r496", "r497", "r498", "r499", "r500", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r548", "r549", "r565", "r566", "r582", "r583", "r584", "r585", "r586", "r587", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r501" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r153", "r154", "r297", "r298", "r303", "r304", "r821" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unamortized Debt Issuance Expense", "terseLabel": "Debt issuance costs", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1004" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Gross unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r441", "r458", "r864" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrual for interest or penalties related to income tax", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r456", "r864" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest or penalties related income tax", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r456", "r864" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases related to current year tax positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r460", "r864" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decreases related to prior year tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r459", "r864" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would affect effective tax rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r461", "r864" ] }, "phat_UnvestedSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "UnvestedSharesMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Unvested shares.", "label": "Unvested Shares [Member]", "terseLabel": "Unvested Shares" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r108", "r109", "r211", "r214", "r215", "r216", "r640", "r642", "r827" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VariableRateAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": [ "r1040", "r1140", "r1194" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VariableRateDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [ "r1040", "r1140", "r1194" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VestingAxis", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "terseLabel": "Vesting", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VestingDomain", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "terseLabel": "Vesting", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173" ] }, "phat_VoqueznaProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "VoqueznaProductMember", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VOQUEZNA Product", "label": "VOQUEZNA Product [Member]", "documentation": "VOQUEZNA Product [Member]", "verboseLabel": "VOQUEZNA TRIPLE PAK" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r973" ] }, "phat_WarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "WarrantExercised", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Exercised", "documentation": "Warrant exercised .", "terseLabel": "Warrant exercised" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "verboseLabel": "Initial fair value of warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1198", "r1199", "r1200" ] }, "phat_WarrantsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.phathompharma.com/20251231", "localname": "WarrantsExpirationDate", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants expiration date.", "label": "Warrants Expiration Date", "terseLabel": "Warrants expiration date" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares of common stock outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r200", "r205" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.phathompharma.com/20251231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares of common stock outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r199", "r205" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r971" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-14" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "330", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-3" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2G", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1022": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1023": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1025": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1026": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1027": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1028": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r1029": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1030": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r1031": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1032": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "50", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718-50/tableOfContent" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }